

Fig. 1. Elution profile of tRNA-cytochrome-c from a HAP column. Batchwise elution of the reaction components was performed as described in Methods. tRNA and cytochrome-c concentrations were measured by absorbance at 260 m μ and 410 m μ , respectively. The column was loaded in 0.01 M NaP, pH 6.8. No A₂₆₀ or A₄₁₀ was observed in the washes with this solvent. The concentrations of tRNA and of cytochrome-c in the elution peaks were calculated as (tRNA) = (A₂₆₀/5.4 $\times 10^5$) mole liter⁻¹ and (cyt-c) = (A₄₁₀/9.6 $\times 10^4$) mole liter⁻¹. The total amounts of tRNA and cytochrome-c in the peak eluting at 0.3 M NaP above are 35 and 34 nmoles, respectively.

molecules such as (RNA)₂-cytochrome-c. The elution profiles vary somewhat with the batch of HAP used and with its preparation. Our results have been reasonably reproducible when the HAP is freshly prepared for each experiment as described in Materials and Methods. Nevertheless it is necessary to monitor the absorbance profiles for each new purification, and to make slight adjustments of the salt concentrations of the elution buffers accordingly.

The final results of all experiments on the preparation of RNA-cytochrome-c and of RNA-cc-biotin are given in table I. The yields of RNA-cytochrome-c in some of the earlier experiments were poor. We now suspect that the *Drosophila* tRNA used was charged with amino acids, but we failed to include a deacylation step, hence the poor yield in these experiments. The best yields with deacylated *E. coli* tRNA are approximately 50%. For 5S RNA it proved necessary to pretreat the cytochrome with iodoacetate to inactivate RNAase, otherwise the 5S RNA was extensively degraded. We believe that this step is advisable for tRNA preparations also, but it was not done in the experiments of table I. Heating the RNA sample to 80° before coupling appears to improve the yield, possibly because it causes dissociation of aggregates formed during lyophilization or ethanol precipitation.

Table I

Effect of Different Treatments on Yields of RNA-cytochrome-c-biotin

RNA	Treatment	% Yield (1:1 RNA/cyto-c)	Molar excess of biotin/RNA	Number of biotins/RNA-cyto-c
<i>E. coli</i> tRNA	no heat step	28.7	50	5
<i>E. coli</i> tRNA	no heat step	12.7	33	3
<i>E. coli</i> tRNA	80°C, 1 min	46	190	7
<i>E. coli</i> tRNA	80°C, 1 min	48	100	7
^a Dm tRNA	80°C, 1 min	11.2	240	9
Dm tRNA	80°C, 1 min	18.7	100	10
^b <i>E. coli</i> 5S rRNA	no heat step	30	100	7
<i>E. coli</i> 5S rRNA	70°C, 10 min	55	100	5
Dm 5SrRNA	70°C, 10 min	56	100	9
Dm 5S rRNA	70°C, 10 min	43	100	5

^aAs mentioned in the text, Dm tRNA was not deacylated and hence lower yields.

^bResults with 5S rRNA are those where cytochrome-c was pretreated with iodoacetate as described in Methods. Initially, when the iodoacetate step was omitted, the yields of the final product were low (0-5%).

As shown in table I, a molar excess of 50-100 fold of NHS-biotin to tRNA-cytochrome-c was used in order to obtain a final product with 3-10 biotins per cytochrome. Control experiments with unconjugated RNA gave undetectable binding of biotin after treatment with NHS-biotin and dialysis.

Cytochrome-c is positively charged and does not elute from the negatively charged resin, CMC, until the NaCl concentration is raised to approximately 5 M, whereas both tRNA and tRNA-cytochrome-c are negatively charged and do not bind to the column even in 0.01 M NaP. The crucial step in the purification is the HAP chromatography step. Unligated cytochrome-c elutes with approximately 0.5 M NaP, free tRNA with about 0.15 M NaP, and the 1 to 1 RNA-cytochrome conjugate at 0.3 M NaP. Several other separation methods were tried without success, including DEAE chromatography both in denaturing and nondenaturing conditions, CsCl centrifugation and gel filtration.

EM Mapping: The ϕ 80psu₃⁻/ ϕ 80 heteroduplex. This heteroduplex is a convenient test system for tRNA mapping techniques. As shown in previous studies (15, 16) and sketched in fig. 2, the heteroduplex loop consists of a 3100 nucleotide segment of *E. coli* DNA and a 2100 nucleotide single-strand

segment of $\phi 80$ DNA. The substitution begins at the att site of $\phi 80$ DNA. The *E. coli* single strand segment contains 1 tRNA^{tyr} gene at a position 1100 nucleotides from the att junction. Electron micrographs of two heteroduplexes labeled with spheres-avidin are shown in fig. 2. Micrographs (not shown) of heteroduplexes labeled with ferritin-avidin are comparable in appearance to those obtained by other methods (2, 15). A histogram of the spheres positions is given in Fig. 3. The results are in accordance with previous mapping data.

A considerable background of free spheres is evident in the micrograph. We have not found a procedure for separating unbound spheres from those attached to DNA, comparable to the sodium iohalamate buoyant banding procedure (1) that can be used to separate free ferritin from ferritin




Fig. 2. Electron micrographs of sphere labeled tRNA genes on $\phi 80/\phi 80\psi_3^-$ heteroduplex. One complete molecule is shown, with an inset sketch of the heteroduplex loop. The att site and the fork at the other end of the substitution loop are 23.8 and 19.3 kb from the left and right ends of the heteroduplex, respectively (15); therefore they are readily distinguished. An inset photograph of the heteroduplex loop of a second molecule is shown; the magnification is 2X that of the other photo. Bar = 1 kb.




Fig. 3. Histogram of map position of tRNA^{tyr} gene on the single strand of bacterial DNA of the $\phi 80/\phi 80$ psu_3^- heteroduplex. The horizontal coordinate is the fractional distance from the att site to the label. The measured position of the label is 1100 (\pm 66) nucleotides from the att site.

labeled heteroduplexes. It may be noted however, that the spheres in the background seem to avoid the DNA strands.

By counting random fields we estimate labeling efficiencies per gene of 50-60% for both ferritin-avidin and the sphere-avidin labels using the cytochrome-c bridge. In experiments with the pentane diamine linker, the labeling efficiency with spheres was negligibly small (N.D. Hershey, personal communication). Presumably the greater length of the cytochrome-c linker is responsible for the efficient labeling in the present method. Nevertheless it should be noted that the efficiency of labeling either with spheres-avidin or ferritin-avidin is at best about 60%. The reason why a figure closer to a 100% is

not achieved is not known.

EM Mapping. Drosophila 4S and 5S genes. Studies from this laboratory on the mapping of 4S RNA genes on a 9.3 kb segment of *Drosophila melanogaster* (Dm) DNA contained on the recombinant DNA plasmid pCIT12 have been reported (7). The mapping data were obtained by EM mapping, using the technique described in detail in the present paper with a ferritin-avidin label, and by restriction endonuclease - hybridization mapping.

Electron micrographs from additional mapping experiments with the avidin-sphere label on the plasmid pCIT12 are shown in fig. 4. A histogram of the observed positions of the tRNA genes on the Dm insert is shown in fig. 5. In the previous study as well as in the present one labeled sites (genes) were found at the 3 positions 4.38 ± 11 , 4.59 ± 0.17 and 8.38 ± 0.26 kb from the defined left end of the Dm insert. An additional gene mapping in the position 5.6 - 6.2 kb was found by restriction endonuclease mapping but was not detected at an appreciable frequency in the ferritin-avidin studies. The histogram in fig. 5 shows that this gene, mapped at 5.89 ± 0.36 kb was labeled at a frequency lower than that for the other genes but at a clearly detectable level in the present sphere-avidin studies. We do not know at present whether this improved labeling efficiency is due to the fact that the avidin spheres contain more avidins per label (8-10) than do the ferritin labels (1-2), or due to some other unknown factor.

Ferritin-avidin mapping studies, using the present techniques, on the recombinant plasmid pCIT9 with an insert carrying 3 Dm 5S RNA genes have been reported (6). *Drosophila* 5S genes are tandemly repeated with a regular spacing of about 380 nucleotides. Our labels -- ferritin-avidin or spheres-avidin-- are multivalent, in that they contain several biotin binding sites per label. Many tangled structures were seen because one label was attached to several hybridized RNA-biotin molecules along a DNA strand. Such molecules cannot be accurately analyzed; nevertheless we have estimated that the overall efficiency of labeling per gene is 40-50% in the various experiments.

As an overall evaluation then, the present method gives 40-60% labeling efficiency in practical problems. Resolution is probably limited by the diameters of the labels - about 200 Å for ferritin-avidin and 600 Å for spheres-avidin. At present, difficulties are encountered with closely spaced genes because of the multivalent character of the labels. Further work is needed to develop a ferritin-avidin conjugate with only one avidin per ferritin and with a high efficiency of labeling, so that closely spaced multiple genes can be mapped.




Fig. 4. Electron micrographs of sphere labeled tRNA genes on a single strand of the recombinant plasmid pCIT12. For a full explanation of the structures, see (7). Briefly, the molecules shown are heteroduplexes of pCIT12, which is ColE1 fused to a 9 kb Dm insert, with a second contaminant plasmid consisting of ColE1 fused to another short Dm insert. A secondary structure feature, fb, on the 9 kb single strand serves to orient that strand. The single tRNA gene labeled in the upper micrograph is at the position 8.38 ± 0.26 in fig. 5; the three sphere labels in the lower micrograph are at the positions 1.38 ± 0.11 , 5.80 ± 0.36 and 8.38 ± 0.26 in fig. 5. In addition there is a sphere nonspecifically attached to the ColE1 duplex. These are rare. Bars = 1 kb.




Fig. 5. Histogram of the distribution of Dm tRNA gene positions on the pCIT12 plasmid. The measurements were done as described (7). In addition to the 3 genes found in the previous ferritin mapping study, a 4th gene at 5.89 kb was labeled here, although to a lesser extent. Its position is in agreement with that determined for the 4th gene by the restriction endonuclease mapping.

Gene Enrichment. In these experiments, high molecular weight *Drosophila* DNA is incubated with 5S RNA-cc-biotin. Hybridization is carried out in a high formamide solvent under conditions where RNA:DNA association is favored over DNA:DNA association (13). Those DNA strands which hybridize to the 5S RNA are separated from all other strands by reaction with avidin-spheres and buoyant banding. These experiments are basically identical to those previously described for the enrichment of the rRNA genes of *Drosophila* (4), except that, as appropriate for the short length of the 5S RNA, we use a terminal cytochrome-c bridge between the RNA and the biotin instead of random crosslinking of cytochrome-biotin to the RNA by CH_2O .

There are 160 5S RNA genes of *Drosophila* (17). They are tandemly repeated with a repeat spacing of about 380 nucleotides. They may occur as two clusters of approximately 80 genes each or there may be a single cluster of length 63.4 kb containing all of the genes, as suggested by restriction digest studies of the chromosomal DNA (17, 18). All told, the genes plus spacers constitute 1.73×10^{-4} of the haploid Dm genome (1.8×10^8 base

pairs). In the present experiments the bulk of the single strands of Dm DNA ranged in length from 10-100 kb. Thus the strands carrying 5S genes would have 25 or more 5S RNA-cc-biotin molecules hybridized. (There is every theoretical reason to expect that the efficiency of RNA:DNA hybridization is almost 100%.) For a strand of length 10 kb with one sphere attached the weight fraction of sphere mass is 0.96. If several spheres are attached per 10 kb the weight fraction is still closer to 1. Thus by the rules formulated by Pellegrini et al. (5) the buoyant density of the DNA sphere complex would be close to that, 1.25 g/ml, of uncomplexed spheres. The efficiency of labeling in the electron microscope experiments was 50% per gene. Just how many avidin-spheres would be bound to a 10 kb strand carrying 25 hybridized 5S RNA-cc-biotin molecules is uncertain because we do not know how many of these biotins would bind to a single avidin-sphere rather than to different avidin-spheres.

The results of several gene enrichment experiments are presented in table II. In all three experiments, almost all (greater than 88%) of the 5S genes were recovered in the enriched fraction. In the first experiment, about 1.5×10^{-2} of the total DNA was in the enriched fraction whereas in the second and third experiments only about 6.5×10^{-4} of the DNA was in the

Table II

Results of Enrichment for 5S rDNA from Total Drosophila DNA

	Z Total DNA in		Z 5S rDNA in		Enrichment Factor
	Enriched	Depleted	Enriched	Depleted	
Theoretical Experiment	0.0173	99.923	100	0	5780
1	1.48	98.52	99.9	not detected	67
2	0.067	99.933	91.5	8.5	1351
3	0.063	99.937	88.8	9.8	1411

The volume of the DNA after the Sepharose 2B step is usually 7-10 ml. The salt concentration is 0.1M. This volume is reduced by evaporation by a factor of 10 and the salt concentration raised to 1.0 M for sphere labeling under conditions of minimal electrostatic interaction between the positive avidins on the spheres and the negative DNA. In the first experiment, the spheres were added before the evaporation step. Perhaps this caused more quasi-irreversible electrostatic binding between spheres and DNA. In experiments 2 and 3, spheres were added after evaporation. In the 3rd experiment, labeling was done at 0° for 48 hr instead of at room temperature for 16-24 hours.

enriched fraction. Therefore in the first experiment the 5S DNA after one cycle of enrichment was about 1% pure, whereas in the second and third experiments it was about 25% pure. In control experiments where no RNA was added approximately 3.4×10^{-4} of the DNA was found in the sphere band. Therefore of the total of about 6.5×10^{-4} DNA in experiments 2 and 3, about 50% may be attributed to general binding or trapping of DNA by the spheres, 25% to specific gene enrichment, and 25% to other causes, possibly formation of networks or partially duplex DNA with a strand bearing a 5S gene (see below).

The two major technical differences between experiment 1 and the more successful experiments 2 and 3 were:

1) In the latter experiments, the excess of unlabeled (no cytochrome-biotin) rRNA (which included 5.8S rRNA as well as 18 and 26S) added was 100 times the amount of 5S RNA, whereas in the first experiment there was only a 15 fold excess. Whereas 5S genes plus spacers make up 1.7×10^{-4} of Dm DNA, rRNA genes plus spacers constitute 6.4×10^{-3} ; therefore it is necessary to completely compete out hybridization of any biotin labeled rRNA fragments present as contaminants in the 5S preparation with the cold rRNA. In their filter hybridization experiments, Tartof and Perry (19) found that it was necessary to use a 100 fold excess of unlabeled rRNA in order to accurately assay for the number of 5S RNA genes.

2) As explained in a footnote to table II, there was a difference in a concentration step of the sphere-avidin-DNA mixture between experiments 1 and experiments 2 and 3 which may have decreased the amount of non-specific binding in the latter.

A small fraction of the sphere band from the CsCl gradient was directly diluted into formamide solution and spread for electron microscopy. The DNA structures observed were of the following types: a) Single strands with one or many spheres. Strands with many spheres were tangled and condensed around the spheres, as expected in view of the close spacing of the genes and the several avidins attached to each sphere. b) Single strands with no spheres attached. These were presumably released from the spheres by breakage. c) Molecules that were partially duplex, due to some DNA:DNA reassociation. d) Networks of single strands, perhaps due to tangling of the long strands in the high salt medium. Factors (c) and (d) may contribute to the amount of non-coding strands in the enriched fraction. The DNA strands observed had about the same length distribution as the input DNA, showing that the gene enrichment procedure does not cause much chain breakage.

Further discussion. In several test systems, the efficiency of labeling with the cytochrome-c-biotin attached to the 3' terminus of 4S and 5S RNA was 50% with either avidin-spheres or ferritin-avidin. The efficiency of labeling by spheres-avidin for cytochrome-biotin randomly crosslinked to RNA with CH_2O is reported to be substantially lower than this figure (4). The present method could be applied to genes for long RNA's as well as for short ones. For long RNA, it would be advantageous to degrade the RNA to a length of 100-400 nucleotides, and expose new 2', 3' OH ends with alkaline phosphatase before coupling to cytochrome-c. Thus one would provide several cytochrome-biotin affinity labels per gene. In general then, the present technique appears to be a very useful addition to methods of gene enrichment and electron microscope gene mapping.

ACKNOWLEDGMENTS. We would like to thank Dr. Maria Pellegrini for helpful discussions on the enrichment experiments. A.S. was the recipient of a fellowship from the California Section of the American Cancer Society. This research has been supported by grant GM 10991 from the United States Public Health Service.

REFERENCES

1. Broker, T.R., Angerer, L.M., Yen, P., Hershey, N.D., and Davidson, N. (1978) *Nucleic Acids Res.*, preceding paper.
2. Angerer, L., Davidson, N., Murphy, W., Lynch, D., and Attardi, G. (1976) *Cell* **9**, 81-90.
3. Manning, J.E., Hershey, N.D., Broker, T.R., Pellegrini, M., Mitchell, H.K. and Davidson, N. (1975) *Chromosoma* **53**, 107-117.
4. Manning, J., Pellegrini, M., and Davidson, N. (1977) *Biochemistry* **16**, 1364-1370.
5. Pellegrini, M., Holmes, D.S. and Manning, J. (1977) *Nucleic Acids Res.*, **4**, 2961-2974.
6. Hershey, N.D., Conrad, S.E., Sodja, A., Cohen, M., Davidson, N., Ilgen, C., and Carbon, J. (1977) *Cell* **11**, 585-598.
7. Yen, P.H., Sodja, A., Cohen, M., Conrad, S.E. Wu, M., Davidson, N., and Ilgen, C. (1977) *Cell* **11**, 763-777.
8. Manning, J.E., Schmid, C.W., and Davidson, N. (1975) *Cell* **4**, 141-155.
9. Gundlach, H.G., Stein, W.H., and Moore, S. (1959) *J. Biol. Chem.* **234**, 1754-1760.
10. Zimmerman, S.B., and Sandeen, G. (1965) *Analyt. Biochem.* **14**, 269-277.
11. Barrel, B.G., Air, G.M., and Hutchison, C.A. III. (1976) *Nature* **264**, 34-41.
12. Orosz, J.M., and Wetmur, J.G. (1974) *Biochem.* **13**, 5467-5473.
13. Casey, J., Davidson, N. (1977) *Nucleic Acids Res.* **4**, 1539-1552.
14. Kotchetkov, N.K., Budovskii, E.I. (eds) (1972) in *Organic Chemistry of Nucleic Acids*, Part B, p. 493 Plenum Press, London and New York.
15. Wu, M., and Davidson, N. (1973) *J. Mol. Biol.* **78**, 1-21.
16. Miller, R.C., Besmer, P., Khorana, H.G., Fianadt, M., and Szybalski, W. (1971) *J. Mol. Biol.* **56**, 363-368.
17. Procurier, J.D., and Tartof, K.D. (1976) *Nature* **263**, 255-257.

18. Artavanis-Tsakonas, S., Schedl, P., Tschudi, C., Pirrotta, V., Steward, R., and Gehring, W.J. (1977) Cell, submitted for publication.
19. Tartof, K.D., and Perry, R.P. (1970) J. Mol. Biol. 51, 171-183.

Dean L. Engelhardt, et al.
Serial No.: 08/479,997
Filed: June 7, 1995

PREVIOUSLY PENDING CLAIMS 454-575
EXHIBIT 3 TO DECLARATION OF DR. ANN SODJA
(IN SUPPORT OF THE NON-OBVIOUSNESS OF THE
INVENTION CLAIMED IN U.S. PATENT APPLICATION
SERIAL NO. 08/479,997
Page 2 (Amendment Under 37 C.F.R. § 1.116 - November 20, 1998)

AMEND THE ABOVE-IDENTIFIED APPLICATION AS FOLLOWS:

In The Specification:

Page 53, line 22, after "ribonucleotide. The" and before "vicinal"
change "3', 4'" to -- 3', 2' --.

In The Claims:

Cancel claims 310-372 and 405-453.

Add new claims 454-573 as follows:

-- 454. (NEW) An oligo- or polydeoxyribonucleotide comprising at least one nucleotide having the formula


Sig - PM - SM - BASE

wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM, said BASE being attached to SM, and Sig being covalently attached to PM directly or via a chemical linkage, said Sig being a moiety capable of non-radioactive detection when attached to PM or when said nucleotide is incorporated into said oligo- or polydeoxyribonucleotide. --


-- 455. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said Sig is or renders the nucleotide self-signaling or self-indicating or self-detecting. --

-- 456. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said Sig moiety comprises at least three carbon atoms. --

-- 457. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said covalent attachment is selected from the group consisting of



and







-- 458. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage does not interfere substantially with the characteristic ability of Sig to form a detectable signal. --

-- 459. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the alpha-position relative to the point of attachment to the nucleotide, a $-\text{CH}_2\text{NH}-$ moiety, or both. --

-- 460. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage comprises an allylamine group. --

-- 461. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage comprises or includes an olefinic bond at the delta-position relative to the point of attachment to the nucleotide, or any of the moieties:



-- 462. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage of Sig includes a glycosidic linkage moiety. --

463. ^{AMENDED} ~~(Revised)~~ The oligo- or polydeoxyribonucleotide of claim 454, wherein said PM is a monophosphate, a diphosphate or a triphosphate and said Sig moiety is covalently attached to said PM through a phosphorus atom or a phosphate oxygen.

-- 464. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein Sig comprises a component selected from the group consisting of biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme or an enzyme component, a hormone or a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten and an antibody or an antibody component, or a combination of any of the foregoing. --

-- 465. (NEW) The oligo- or polydeoxyribonucleotide of claim 464, wherein said electron dense component comprises ferritin. --

- 466. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein Sig is complexed with a binding protein therefor, and said binding protein is conjugated to ferritin. --
- 467. (NEW) The oligo- or polydeoxyribonucleotide of claim 464, wherein said magnetic component comprises magnetic oxide. --
- 468. (NEW) The oligo- or polydeoxyribonucleotide of claim 467, wherein said magnetic oxide comprises ferric oxide. --
- 469. (NEW) The oligo- or polydeoxyribonucleotide of claim 464, wherein said enzyme or enzyme component is selected from the group consisting of alkaline phosphatase, acid phosphatase, β -galactosidase, ribonuclease, glucose oxidase and peroxidase. --
- 470. (NEW) The oligo- or polydeoxyribonucleotide of claim 464, wherein said metal-containing component is catalytic. --
- 471. (NEW) The oligo- or polydeoxyribonucleotide of claim 464, wherein said fluorescent component comprises a member selected from the group consisting of fluorescein, rhodamine and dansyl. --
- 472. (NEW) The oligo- or polydeoxyribonucleotide of claim 464, wherein Sig is selected from the group consisting of an antigen or hapten capable of complexing with an antibody or antibody component specific thereto, and an antibody or antibody component capable of complexing with an antigen or hapten. --
- 473. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said oligo- or polydeoxyribonucleotide is terminally ligated or attached to a polypeptide. --
- 474. (NEW) A composition comprising the oligo- or polydeoxyribonucleotide of claim 454, a polypeptide capable of forming a complex with Sig and a moiety which can be detected when such complex is formed. --

Dean L. Engelhardt, *et al.*

Serial No.: 08/479,997

Filed: June 7, 1995

Page 6 (Amendment Under 37 C.F.R. § 1.116 - November 20, 1998)

-- 475. (NEW) The composition of claim 474, wherein said polypeptide comprises polylysine. --

-- 476. (NEW) The composition of claim 474, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and anti-Sig immunoglobulin. --

--477. (NEW) The composition of claim 474, wherein Sig is a ligand and said polypeptide is an antibody thereto. --


-- 478. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, wherein said Sig moiety is attached to a terminal nucleotide in said oligo- or polydeoxyribonucleotide. --

AMENDED
479. (~~Re-written~~) The oligo- or polydeoxyribonucleotide of claim 478, wherein the sugar moiety of said terminal nucleotide has a hydrogen atom at the 2' position thereof.

AMENDED
480. (~~Re-written~~) The oligo- or polydeoxyribonucleotide of claim 478, wherein the sugar moiety of said terminal nucleotide has hydrogen atoms at each of the 2' and 3' positions thereof.

-- 481. (NEW) The oligo- or polydeoxyribonucleotide of claim 454, comprising at least one ribonucleotide. --

-- 482. (NEW) An oligo- or polydeoxyribonucleotide comprising at least one nucleotide having the structural formula:



wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x is selected from the group consisting of H-, HO-, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of H-, HO-, a mono-phosphate, a di-phosphate and a tri-phosphate;


wherein z is H-; and

wherein Sig is covalently attached to x, y or z directly or through a chemical linkage, said Sig being a moiety capable of non-radioactive detection when so attached to x, y or z. --


-- 483. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said Sig is or renders the nucleotide or the oligo- or polynucleotide self-signaling or self-indicating or self-detecting. --

-- 484. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said Sig moiety comprises at least three carbon atoms. --

-- 485. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said covalent attachment is selected from the group consisting of



and







-- 486. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage does not interfere substantially with the characteristic ability of Sig to form a detectable signal. --

-- 487. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the alpha-position relative to the point of attachment to the nucleotide, a $-\text{CH}_2\text{NH}-$ moiety, or both. --

-- 488. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage comprises an allylamine group. --

-- 489. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage comprises or includes an olefinic bond at the delta-position relative to x, y or z, or any of the moieties:



-- 490. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage of Sig includes a glycosidic linkage moiety. --

~~491. (Amended)~~
^{AMENDED}
491. (Amended) The oligo- or polydeoxyribonucleotide of claim 482, wherein said x and y each comprise a member selected from the group consisting of a monophosphate, a diphosphate and a triphosphate and said Sig moiety is covalently attached to either or both of said x and y through a phosphorus atom or a phosphate oxygen.

-- 492. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein Sig comprises a component selected from the group consisting of biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme or an enzyme component, a hormone or a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten and an antibody or an antibody component, or a combination of any of the foregoing. --

-- 493. (NEW) The oligo- or polydeoxyribonucleotide of claim 492, wherein said electron dense component comprises ferritin. --

-- 494. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein Sig is complexed with a binding protein therefor, and said binding protein is conjugated to ferritin. --

-- 495. (NEW) The oligo- or polydeoxyribonucleotide of claim 492, wherein said magnetic component comprises magnetic oxide. --

-- 496. (NEW) The oligo- or polydeoxyribonucleotide of claim 495, wherein said magnetic oxide comprises ferric oxide. --

-- 497. (NEW) The oligo- or polydeoxyribonucleotide of claim 492, wherein said enzyme or enzyme component is selected from the group consisting of alkaline phosphatase, acid phosphatase, β -galactosidase, ribonuclease, glucose oxidase and peroxidase. --

-- 498. (NEW) The oligo- or polydeoxyribonucleotide of claim 492, wherein said metal-containing component is catalytic. --

-- 499. (NEW) The oligo- or polydeoxyribonucleotide of claim 492, wherein said fluorescent component comprises a member selected from the group consisting of fluorescein, rhodamine and dansyl. --

-- 500. (NEW) The oligo- or polydeoxyribonucleotide of claim 492, wherein Sig is selected from the group consisting of an antigen or hapten capable of complexing with an antibody or antibody component specific thereto, and an antibody or antibody component capable of complexing with an antigen or hapten. --

-- 501. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said oligo- or polydeoxyribonucleotide is terminally ligated or attached to a polypeptide. --

-- 502. (NEW) A composition comprising the oligo- or polydeoxyribonucleotide of claim 482, a polypeptide capable of forming a complex with Sig and a moiety which can be detected when such complex is formed. --

- 503. (NEW) The composition of claim 500, wherein said polypeptide comprises polylysine. --
- 504. (NEW) The composition of claim 502, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and anti-Sig immunoglobulin. --
- 505. (NEW) The composition of claim 502, wherein Sig is a ligand and said polypeptide is an antibody thereto. --
- 506. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, wherein said Sig moiety is attached to a terminal nucleotide in said oligo- or polydeoxyribonucleotide. --
507. ^{AMENDED} (Rewritten) The oligo- or polydeoxyribonucleotide of claim 506, wherein z of said terminal nucleotide comprises a hydrogen atom at the 2' position thereof.
508. ^{AMENDED} (Rewritten) The oligo- or polydeoxyribonucleotide of claim 506, wherein both y and z of said terminal nucleotide comprise a hydrogen atom at each of the 3' and 2' positions thereof, respectively.
- 509. (NEW) The oligo- or polydeoxyribonucleotide of claim 482, comprising at least one ribonucleotide. --

The diagram illustrates a branched polysaccharide structure with three distinct repeating units, labeled *m*, *n*, and *p*.

- Unit *m*:** This unit is enclosed in large square brackets with a subscript *m*. It features a pyranose ring (six-membered ring) in a chair conformation. The anomeric carbon (C1) is linked to a phosphate group, which is further connected to a hydroxyl group (OH-P(=O)(OH)-). The C2 position is substituted with a B' group. The C3 position is linked to a phosphate group, which is connected to a hydroxyl group (OH-P(=O)(OH)-). The C4 position is linked to a CH₂ group, which is connected to a pyranose ring in unit *n*.
- Unit *n*:** This unit is also enclosed in large square brackets with a subscript *n*. It features a pyranose ring in a chair conformation. The anomeric carbon (C1) is linked to a phosphate group, which is further connected to a hydroxyl group (OH-P(=O)(OH)-). The C2 position is substituted with a B'' group. The C3 position is linked to a phosphate group, which is connected to a hydroxyl group (OH-P(=O)(OH)-). The C4 position is linked to a CH₂ group, which is connected to a pyranose ring in unit *p*.
- Unit *p*:** This unit is enclosed in large square brackets with a subscript *p*. It features a pyranose ring in a chair conformation. The anomeric carbon (C1) is linked to a phosphate group, which is further connected to a hydroxyl group (OH-P(=O)(OH)-). The C2 position is substituted with a B'' group. The C3 position is linked to a phosphate group, which is connected to a hydroxyl group (OH-P(=O)(OH)-). The C4 position is linked to a CH₂ group, which is connected to a pyranose ring in unit *n*.


The structure shows a complex branching pattern where the units are interconnected through their phosphate and CH₂ groups, forming a branched network.

Enz-5(D6)(C2)


-- 512. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said Sig is or renders the nucleotide self-signaling or self-indicating or self-detecting. --

-- 513. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said Sig moiety comprises at least three carbon atoms. --

-- 514. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said covalent attachment is selected from the group consisting of



and







-- 515. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said chemical linkage does not interfere substantially with the characteristic ability of Sig to form a detectable signal. --

-- 516. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the alpha-position relative to the point of attachment to the nucleotide, a $-\text{CH}_2\text{NH}-$ moiety, or both. --

-- 517. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said chemical linkage comprises an allylamine group. --

-- 518. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said chemical linkage comprises or includes an olefinic bond at the delta-position relative to the point of attachment to the nucleotide, or any of the moieties:



-- 519. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said chemical linkage of Sig includes a glycosidic linkage moiety. --

AMENDED

520. ~~(New)~~ The oligo- or polyribonucleotide of claim 511, wherein said PM is a monophosphate, a diphosphate or a triphosphate and said Sig moiety is covalently attached to said PM through a phosphorus atom or a phosphate oxygen.

-- 521. (NEW) The oligo- or polyribonucleotide of claim 511, wherein Sig comprises a component selected from the group consisting of biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme or an enzyme component, a hormone or a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten and an antibody or an antibody component, or a combination of any of the foregoing. --

-- 522. (NEW) The oligo- or polyribonucleotide of claim 521, wherein said electron dense component comprises ferritin. --

-- 523. (NEW) The oligo- or polyribonucleotide of claim 511, wherein Sig is complexed with a binding protein therefor, and said binding protein is conjugated to ferritin. --

-- 524. (NEW) The oligo- or polyribonucleotide of claim 521, wherein said magnetic component comprises a magnetic oxide. --

-- 525. (NEW) The oligo- or polyribonucleotide of claim 524, wherein said magnetic oxide comprises ferric oxide. --

-- 526. (NEW) The oligo- or polyribonucleotide of claim 521, wherein said enzyme or enzyme component is selected from the group consisting of alkaline phosphatase, acid phosphatase, β -galactosidase, ribonuclease, glucose oxidase and peroxidase. --

-- 527. (NEW) The oligo- or polyribonucleotide of claim 521, wherein said metal-containing component is catalytic. --

-- 528. (NEW) The oligo- or polyribonucleotide of claim 521, wherein said fluorescent component comprises a member selected from the group consisting of fluorescein, rhodamine and dansyl. --

-- 529. (NEW) The oligo- or polyribonucleotide of claim 521, wherein Sig is selected from the group consisting of an antigen or hapten capable of complexing with an antibody or antibody component specific thereto, and an antibody or antibody component capable of complexing with an antigen or hapten. --

-- 530. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said oligo- or polyribonucleotide is terminally ligated or attached to a polypeptide. --

-- 531. (NEW) A composition comprising the oligo- or polyribonucleotide of claim 511, a polypeptide capable of forming a complex with Sig and a moiety which can be detected when such complex is formed. --

-- 532. (NEW) The composition of claim 531, wherein said polypeptide comprises polylysine. --

Dean L. Engelhardt, *et al.*

Serial No.: 08/479,997

Filed: June 7, 1995

Page 16 (Amendment Under 37 C.F.R. § 1.116 – November 20, 1998)

-- 533. (NEW) The composition of claim 531, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and anti-Sig immunoglobulin. --

-- 534. (NEW) The composition of claim 531, wherein Sig is a ligand and said polypeptide is an antibody thereto. --


-- 535. (NEW) The oligo- or polyribonucleotide of claim 511, wherein said Sig moiety is attached to a terminal ribonucleotide in said oligo- or polyribonucleotide. --

-- 536. (NEW) The oligo- or polyribonucleotide of claim 535, wherein the sugar moiety of said terminal ribonucleotide has a hydrogen atom at the 2' position thereof. --

-- 537. (NEW) The oligo- or polyribonucleotide of claim 535, wherein the sugar moiety of said terminal nucleotide has a hydrogen atom at each of the 2' and 3' positions thereof. --

-- 538. (NEW) The oligo- or polyribonucleotide of claim 511, comprising at least one deoxyribonucleotide. --

-- 539. (NEW) An oligo- or polyribonucleotide comprising at least one nucleotide having the structural formula:



wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x is selected from the group consisting of H-, HO-, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of HO-, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein z is HO-; and

wherein Sig is covalently attached to x, y or z directly or through a chemical linkage, said Sig being a moiety capable of non-radioactive detection when so attached to x, y or z, provided that when Sig is attached through a chemical linkage to y of a terminal ribonucleotide, said chemical linkage is not a cleaved 3' terminal ribonucleotide previously attached to said oligo- or polyribonucleotide. --

-- 540. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said Sig is or renders the nucleotide or the oligo- or polynucleotide self-signaling or self-indicating or self-detecting. --

-- 541. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said Sig moiety comprises at least three carbon atoms. --


Dean L. Engelhardt, *et al.*

Serial No.: 08/479,997


Filed: June 7, 1995

Page 18 (Amendment Under 37 C.F.R. § 1.116 – November 20, 1998)

-- 542. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said covalent attachment is selected from the group consisting of



and







-- 543. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said chemical linkage does not interfere substantially with the characteristic ability of Sig to form a detectable signal. --

-- 544. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the alpha-position relative to the point of attachment to the nucleotide, a $-\text{CH}_2\text{NH}-$ moiety, or both. --

-- 545. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said chemical linkage comprises an allylamine group. --

-- 546. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said chemical linkage comprises or includes an olefinic bond at the delta-position relative to x, y or z, or any of the moieties:



-- 547. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said chemical linkage of Sig includes a glycosidic linkage moiety. --

AMENDED

548. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said x and y each comprise a member selected from the group consisting of a monophosphate, a diphosphate and a triphosphate and said Sig moiety is covalently attached to either or both of said x and y through a phosphorus atom or a phosphate oxygen.

-- 549. (NEW) The oligo- or polyribonucleotide of claim 539, wherein Sig comprises a component selected from the group consisting of biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme or an enzyme component, a hormone or a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten and an antibody or an antibody component, or a combination of any of the foregoing. --

-- 550. (NEW) The oligo- or polyribonucleotide of claim 549, wherein said electron dense component comprises ferritin. --

- 551. (NEW) The oligo- or polyribonucleotide of claim 539, wherein Sig is complexed with a binding protein therefor, and said binding protein is conjugated to ferritin. --
- 552. (NEW) The oligo- or polyribonucleotide of claim 549, wherein said magnetic component comprises magnetic oxide. --
- 553. (NEW) The oligo- or polyribonucleotide of claim 552, wherein said magnetic oxide comprises ferric oxide. --
- 554. (NEW) The oligo- or polyribonucleotide of claim 549, wherein said enzyme or enzyme component is selected from the group consisting of alkaline phosphatase, acid phosphatase, β -galactosidase, ribonuclease, glucose oxidase and peroxidase. --
- 555. (NEW) The oligo- or polyribonucleotide of claim 549, wherein said metal-containing component is catalytic. --
- 556. (NEW) The oligo- or polyribonucleotide of claim 549, wherein said fluorescent component comprises a member selected from the group consisting of fluorescein, rhodamine and dansyl. --
- 557. (NEW) The oligo- or polyribonucleotide of claim 549, wherein Sig is selected from the group consisting of an antigen or hapten capable of complexing with an antibody or antibody component specific thereto, and an antibody or antibody component capable of complexing with an antigen or hapten. --
- 558. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said oligo- or polyribonucleotide is terminally ligated or attached to a polypeptide. --
- 559. (NEW) A composition comprising the oligo- or polyribonucleotide of claim 539, a polypeptide capable of forming a complex with Sig and a moiety which can be detected when such complex is formed. --
- 560. (NEW) The composition of claim 559, wherein said polypeptide comprises polylysine. --

-- 561. (NEW) The composition of claim 559, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and anti-Sig immunoglobulin. --

-- 562. (NEW) The composition of claim 559, wherein Sig is a ligand and said polypeptide is an antibody thereto. --


-- 563. (NEW) The oligo- or polyribonucleotide of claim 539, wherein said Sig moiety is attached to a terminal nucleotide in said oligo- or polyribonucleotide. --

~~564. (Revritten)~~ ^{AMENDED} The oligo- or polyribonucleotide of claim 563, wherein z of said terminal nucleotide comprises a hydrogen atom at the 2' position thereof.

~~565. (Revritten)~~ ^{AMENDED} The oligo- or polyribonucleotide of claim 563, wherein both y and z of said terminal nucleotide comprise a hydrogen atom at each of the 3' and 2' positions thereof, respectively.


-- 566. (NEW) The oligo- or polyribonucleotide of claim 539, comprising at least one deoxyribonucleotide. --

-- 567. (NEW) The oligo- or polyribonucleotide of claim 539, having the structural formula:



wherein said Sig moiety is attached to at least one of the phosphate moieties in said structural formula. --


-- 568. (NEW) A composition comprising a polymeric compound having attached directly or indirectly thereto at least one deoxyribonucleotide having the formula:



wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM, said BASE being attached to SM, and Sig being covalently attached to PM directly or via a chemical linkage, said Sig being a moiety capable of non-radioactive detection when attached to PM or when said deoxyribonucleotide is incorporated into said composition. --

-- 569. (NEW) The composition of claim 568, wherein said polymeric compound is selected from the group consisting of an oligo- or polynucleotide, an oligo- or polypeptide, and an oligo- or polysaccharide. --

-- 570. (NEW) A composition comprising a polymeric compound attached directly or indirectly to at least one deoxyribonucleotide having the structural formula:



wherein BASE is selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x comprises a member selected from the group consisting of: H- , HO- , a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y comprises a member selected from the group consisting of: H- , HO- , a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein z comprises H- ; and

wherein Sig is covalently attached to x, y or z directly or through a chemical linkage, said Sig being a moiety capable of non-radioactive detection when so attached to x, y or z. --

-- 571. (NEW) The composition of claim 570, wherein said polymeric compound is selected from the group consisting of an oligo- or polynucleotide, an oligo- or polypeptide, and an oligo- or polysaccharide. --


Dean L. Engelhardt, *et al.*

Serial No.: 08/479,997

Filed: June 7, 1995

Page 24 (Amendment Under 37 C.F.R. § 1.116 – November 20, 1998)


-- 572. (NEW) A composition comprising a polymeric compound having attached directly or indirectly thereto at least one ribonucleotide having the formula:



wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM at a position of SM selected from 2', 3' and 5', or combinations thereof, said BASE being attached to SM, and Sig being covalently attached to PM directly or via a chemical linkage, said Sig being a moiety capable of non-radioactive detection when attached to PM or when said ribonucleotide is incorporated into said composition, provided that when Sig is attached through a chemical linkage to a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not a cleaved 3' terminal ribonucleotide previously attached to said composition. --

-- 573. (NEW) The composition of claim 572, wherein said polymeric compound is selected from the group consisting of an oligo- or polynucleotide, an oligo- or polypeptide, and an oligo- or polysaccharide. --

-- 574. (NEW) A composition comprising a polymeric compound having attached directly or indirectly thereto at least one nucleotide having the structural formula:



wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x is selected from the group consisting of H-, HO-, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of HO-, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein z is HO-; and

wherein Sig is covalently attached to x, y or z directly or through a chemical linkage, said Sig being a moiety capable of non-radioactive detection when so attached to x, y or z, provided that when Sig is attached through a chemical linkage to y of a terminal ribonucleotide, said chemical linkage is not a cleaved 3' terminal ribonucleotide previously attached to said composition, --

-- 575. (NEW) The composition of claim 572, wherein said polymeric compound is selected from the group consisting of an oligo- or polynucleotide, an oligo- or polypeptide, and an oligo- or polysaccharide. --

* * * * *


ENGELHARDT ET AL., U.S. PAT. APPL. SER. NO. 08/479,997
AMENDMENTS TO INDEPENDENT CLAIMS 454, 482, 511 & 539
(To Be Effected By Applicants' January 18, 2001 Amendment Under 37 C.F.R. §1.116)
Exhibit 4 to Declaration Of Dr. Ann Sodja (In Support Of The Non-Obviousness Of
The Invention Claimed In U.S. Patent Application Serial No. 08/479,997)]

454. (Amended) An oligo- or polydeoxynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polydeoxynucleotide comprising at least one modified nucleotide having the formula

Sig-PM-SM-BASE

wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a base moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM, said BASE being attached to SM, and Sig being covalently attached to PM directly or through a chemical linkage, said Sig [being a moiety capable non-radioactive detection] comprising a non-radioactive label moiety which can be directly or indirectly detected when attached to PM or when said modified nucleotide is incorporated into said oligo- or polydeoxynucleotide or when said oligo- or polydeoxynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof.

482. (Amended) An oligo- or polydeoxyribonucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polydeoxyribonucleotide comprising at least one modified nucleotide having the structural formula:



wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;


wherein x is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein z is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate; and


wherein Sig is covalently attached [to x, y or z] directly or through a chemical linkage to at least one phosphate selected from the group consisting of x, y, z, and a combination thereof, said Sig [being a moiety capable of non-radioactive detection] comprising a non-radioactive label moiety which can be directly or indirectly detected when so attached to [x, y or z] said phosphate or when said modified nucleotide is incorporated into said oligo- or polydeoxynucleotide or when said oligo- or polydeoxynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof.

511. (Amended) An oligo- or [polyribonucleotide] polynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polynucleotide comprising at least one [ribonucleotide] modified nucleotide having the formula



wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM [at a position of SM selected from the 2', 3' and 5' positions, or combinations thereof], said BASE being attached to SM, and Sig being covalently attached to PM directly or via a chemical linkage, said Sig [being a moiety capable of non-radioactive detection] comprising a non-radioactive label moiety which can be directly or indirectly detected when attached to PM or when said modified nucleotide is incorporated into said oligo- or [polyribonucleotide] polynucleotide, or when said oligo- or polynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof, provided that when said oligo- or polynucleotide is an oligoribonucleotide or a polyribonucleotide, and when Sig is attached through a chemical linkage to a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not [a cleaved 3' terminal ribonucleotide] obtained through a 2',3' vicinal oxidation of a 3' terminal ribonucleotide previously attached to said [oligo- or polyribonucleotide] oligoribonucleotide or polyribonucleotide.

539. (Amended) An oligo- or [polyribonucleotide] polynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polynucleotide comprising at least one modified nucleotide having the structural formula:




wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein z is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate; and
 wherein Sig is covalently attached [to x, y or z] directly or through a chemical linkage to at least one phosphate selected from the group consisting of x, y and z, and a combination thereof, said Sig [being a moiety capable of non-radioactive detection] comprising a non-radioactive label moiety which can be directly or indirectly detected when so attached to [x, y or z] said phosphate or when said modified nucleotide is incorporated into said oligo- or polynucleotide, or when said oligo- or polynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof, provided that when said oligo- or polynucleotide is an oligoribonucleotide or a polyribonucleotide and when Sig is attached through a chemical linkage to [y of] a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not [a cleaved 3' terminal ribonucleotide] obtained through a 2',3' vicinal oxidation of a 3' terminal ribonucleotide previously attached to said [oligo- or polyribonucleotide] oligoribonucleotide or polyribonucleotide.

454. An oligo- or polydeoxynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polydeoxynucleotide comprising at least one modified nucleotide having the formula




wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a base moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM, said BASE being attached to SM, and Sig being covalently attached to PM directly or through a chemical linkage, said Sig comprising a non-radioactive label moiety which can be directly or indirectly detected when attached to PM or when said modified nucleotide is incorporated into said oligo- or polydeoxynucleotide or when said oligo- or polydeoxynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof.

455. The oligo- or polydeoxyribonucleotide of claim 454, wherein said Sig is or renders the nucleotide or the oligo- or polydeoxyribonucleotide self-signaling or self-indicating or self-detecting.

456. The oligo- or polydeoxyribonucleotide of claim 454, wherein said Sig moiety comprises at least three carbon atoms.

457. The oligo- or polydeoxyribonucleotide of claim 454, wherein said covalent attachment is selected from the group consisting of






458. The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage does not interfere substantially with the characteristic ability of Sig to form a detectable signal.

459. The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the α -position relative to the point of attachment to the nucleotide, a $-\text{CH}_2\text{NH}-$ moiety, or both.

460. The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage comprises an allylamine group.

461. The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage comprises or includes an olefinic bond at the α -position relative to the point of attachment to the nucleotide, or any of the moieties:



462. The oligo- or polydeoxyribonucleotide of claim 454, wherein said chemical linkage of Sig includes a glycosidic linkage moiety.

463. The oligo- or polydeoxyribonucleotide of claim 454, wherein said PM is monophosphate, a diphosphate or a triphosphate and said Sig moiety is covalently attached to said PM through a phosphorus atom or phosphate oxygen.

464. The oligo- or polydeoxyribonucleotide of claim 454, wherein Sig comprises a component selected from the group consisting of biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme or an enzyme component, a hormone or a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten and an antibody or an antibody component, or a combination of any of the foregoing.

465. The oligo- or polydeoxyribonucleotide of claim 464, wherein said electron dense component comprises ferritin.
466. The oligo- or polydeoxyribonucleotide of claim 454, wherein Sig is selected from the group consisting of a ligand and a specific ligand binding protein.
467. The oligo- or polydeoxyribonucleotide of claim 464, wherein said magnetic component comprises magnetic oxide.
468. The oligo- or polydeoxyribonucleotide of claim 467, wherein said magnetic oxide comprises ferric oxide.
469. The oligo- or polydeoxyribonucleotide of claim 464, wherein said enzyme or enzyme component is selected from the group consisting of alkaline phosphatase, acid phosphatase, β -galactosidase, ribonuclease, glucose oxidase and peroxidase.
470. The oligo- or polydeoxyribonucleotide of claim 464, wherein said metal-containing component is catalytic.
471. The oligo- or polydeoxyribonucleotide of claim 464, wherein said fluorescent component comprises a member selected from the group consisting of fluorescein, rhodamine and dansyl.
472. The oligo- or polydeoxyribonucleotide of claim 464, wherein Sig is selected from the group consisting of an antigen or hapten capable of complexing with an antibody or antibody component specific thereto, and an antibody or antibody component capable of complexing with an antigen or hapten.
473. The oligo- or polydeoxyribonucleotide of claim 454, wherein said oligo- or polydeoxyribonucleotide is terminally ligated or attached to a polypeptide.

474. A composition comprising the oligo- or polydeoxyribonucleotide of claim 454, a polypeptide capable of forming a complex with Sig and a moiety which can be detected when such complex is formed.

475. The composition of claim 474, wherein said polypeptide comprises polylysine.

476. The composition of claim 474, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and anti-hapten immunoglobulin.

477. The composition of claim 474, wherein said Sig is a ligand and said polypeptide is an antibody thereto.


478. The oligo- or polydeoxyribonucleotide of claim 454, wherein said Sig moiety is attached to a terminal nucleotide in said oligo- or polydeoxyribonucleotide.

479. The oligo- or polydeoxyribonucleotide of claim 478, wherein the sugar moiety of said terminal nucleotide has a hydrogen atom at the 2' position thereof.

480. The oligo- or polydeoxyribonucleotide of claim 478, wherein the sugar moiety of said terminal nucleotide has oxygen atoms at each of the 2' and 3' positions thereof.

481. The oligo- or polydeoxyribonucleotide of claim 454, comprising at least one ribonucleotide.

482. An oligo- or polydeoxyribonucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polydeoxyribonucleotide comprising at least one modified nucleotide having the structural formula:



wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;


wherein z is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate; and

wherein Sig is covalently attached directly or through a chemical linkage to at least one phosphate selected from the group consisting of x, y, z, and a combination thereof, said Sig comprising a non-radioactive label moiety which can be directly or indirectly detected when so attached to said phosphate or when said modified nucleotide is incorporated into said oligo- or polydeoxynucleotide or when said oligo- or polydeoxynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof.

483. The oligo- or polydeoxyribonucleotide of claim 482, wherein said Sig is or renders the nucleotide or the oligo- or polydeoxyribonucleotide self-signaling or self-indicating or self-detecting.

484. The oligo- or polydeoxyribonucleotide of claim 482, wherein said Sig moiety comprises at least three carbon atoms.

485. The oligo- or polydeoxyribonucleotide of claim 482, wherein said covalent attachment is selected from the group consisting of




486. The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage does not interfere substantially with the characteristic ability of Sig to form a detectable signal.

487. The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the α -position relative to the point of attachment to the nucleotide, a $-\text{CH}_2\text{NH}-$ moiety, or both.

488. The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage comprises an allylamine group.

489. The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage comprises or includes an olefinic bond at the α -position relative to the point of attachment to x, y or z, or any of the moieties:




490. The oligo- or polydeoxyribonucleotide of claim 482, wherein said chemical linkage of Sig includes a glycosidic linkage moiety.
491. The oligo- or polydeoxyribonucleotide of claim 482, wherein said x and y each comprise a member selected from the group consisting of a monophosphate, a diphosphate and a triphosphate and said Sig moiety is covalently attached to either or both of said x and y a phosphorus atom or phosphate oxygen.
492. The oligo- or polydeoxyribonucleotide of claim 482, wherein Sig comprises a component selected from the group consisting of biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme or an enzyme component, a hormone or a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten and an antibody or an antibody component, or a combination of any of the foregoing.
493. The oligo- or polydeoxyribonucleotide of claim 492, wherein said electron dense component comprises ferritin.
494. The oligo- or polydeoxyribonucleotide of claim 482, wherein Sig is selected from the group consisting of a ligand and a specific ligand binding protein.
495. The oligo- or polydeoxyribonucleotide of claim 492, wherein said magnetic component comprises magnetic oxide.
496. The oligo- or polydeoxyribonucleotide of claim 495, wherein said magnetic oxide comprises ferric oxide.
497. The oligo- or polydeoxyribonucleotide of claim 492, wherein said enzyme or enzyme component is selected from the group consisting of alkaline phosphatase, acid phosphatase, β -galactosidase, ribonuclease, glucose oxidase and peroxidase.
498. The oligo- or polydeoxyribonucleotide of claim 492, wherein said metal-containing component is catalytic.

499. The oligo- or polydeoxyribonucleotide of claim 492, wherein said fluorescent component comprises a member selected from the group consisting of fluorescein, rhodamine and dansyl.
500. The oligo- or polydeoxyribonucleotide of claim 492, wherein Sig is selected from the group consisting of an antigen or hapten capable of complexing with an antibody or antibody component specific thereto, and an antibody or antibody component capable of complexing with an antigen or hapten.
501. The oligo- or polydeoxyribonucleotide of claim 482, wherein said oligo- or polydeoxyribonucleotide is terminally ligated or attached to a polypeptide.
502. A composition comprising the oligo- or polydeoxyribonucleotide of claim 482, a polypeptide capable of forming a complex with Sig and a moiety which can be detected when such complex is formed.
503. The composition of claim 500, wherein said polypeptide comprises polylysine.
504. The composition of claim 502, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and anti-hapten immunoglobulin.
505. The composition of claim 502, wherein said Sig is a ligand and said polypeptide is an antibody thereto.
506. The oligo- or polydeoxyribonucleotide of claim 482, wherein said Sig moiety is attached to a terminal nucleotide in said oligo- or polydeoxyribonucleotide.
507. The oligo- or polydeoxyribonucleotide of claim 506, wherein z of said terminal nucleotide comprises a hydrogen atom at the 2' position thereof.
508. The oligo- or polydeoxyribonucleotide of claim 506, wherein both y and z of said terminal nucleotide comprise an oxygen atom at each of the 3' and 2' positions thereof, respectively.


509. The oligo- or polydeoxyribonucleotide of claim 482, comprising at least one ribonucleotide.

510. The oligo- or polydexoyribonucleotide of claim 482, having the structural formula:



, wherein m and n represent integers from 0 up to about 100,000, and wherein said Sig moiety is attached to at least one of the phosphate moieties in said structural formula.

511. An oligo- or polynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polynucleotide comprising at least one modified nucleotide having the formula




wherein PM is a phosphate moiety, SM is a sugar moiety and BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, said PM being attached to SM, said BASE being attached to SM, and Sig being covalently attached to PM directly or via a chemical linkage, said Sig comprising a non-radioactive label moiety which can be directly or indirectly detected when attached to PM or when said modified nucleotide is incorporated into said oligo- or polynucleotide, or when said oligo- or polynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof, provided that when said oligo- or polynucleotide is an oligoribonucleotide or a polyribonucleotide, and when Sig is attached through a chemical linkage to a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not obtained through a 2',3' vicinal oxidation of a 3' terminal ribonucleotide previously attached to said oligoribonucleotide or polyribonucleotide.

512. The oligo- or polynucleotide of claim 511, wherein said Sig is or renders the nucleotide or the oligo- or polynucleotide self-signaling or self-indicating or self-detecting.

513. The oligo- or polynucleotide of claim 511, wherein said Sig moiety comprises at least three carbon atoms.

514. The oligo- or polynucleotide of claim 511, wherein said covalent attachment is selected from the group consisting of






515. The oligo- or polynucleotide of claim 511, wherein said chemical linkage does not interfere substantially with the characteristic ability of Sig to form a detectable signal.

516. The oligo- or polynucleotide of claim 511, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the α -position relative to the point of attachment to the nucleotide, a $-\text{CH}_2\text{NH}-$ moiety, or both.

517. The oligo- or polynucleotide of claim 511, wherein said chemical linkage comprises an allylamine group.

518. The oligo- or polynucleotide of claim 511, wherein said chemical linkage comprises or includes an olefinic bond at the α -position relative to the point of attachment to the nucleotide, or any of the moieties:




519. The oligo- or polynucleotide of claim 511, wherein said chemical linkage of Sig includes a glycosidic linkage moiety.

520. The oligo- or polynucleotide of claim 511, wherein said PM is a monophosphate, a diphosphate or a triphosphate and said Sig moiety is covalently attached to said PM through a phosphorus atom or a phosphate oxygen.

521. The oligo- or polynucleotide of claim 511, wherein Sig comprises a component selected from the group consisting of biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme or an enzyme component, a hormone or a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten and an antibody or an antibody component, or a combination of any of the foregoing.
522. The oligo- or polynucleotide of claim 521, wherein said electron dense component comprises ferritin.
523. The oligo- or polynucleotide of claim 511, wherein Sig is selected from the group consisting of a ligand and a specific ligand binding protein.
524. The oligo- or polynucleotide of claim 521, wherein said magnetic component comprises magnetic oxide.
525. The oligo- or polynucleotide of claim 524, wherein said magnetic oxide comprises ferric oxide.
526. The oligo- or polynucleotide of claim 521, wherein said enzyme or enzyme component is selected from the group consisting of alkaline phosphatase, acid phosphatase, β -galactosidase, ribonuclease, glucose oxidase and peroxidase.
527. The oligo- or polynucleotide of claim 521, wherein said metal-containing component is catalytic.
528. The oligo- or polynucleotide of claim 521, wherein said fluorescent component comprises a member selected from the group consisting of fluorescein, rhodamine and dansyl.
529. The oligo- or polynucleotide of claim 521, wherein Sig is selected from the group consisting of an antigen or hapten capable of complexing with an antibody or antibody component specific thereto, and an antibody or antibody component capable of complexing with an antigen or hapten.

530. The oligo- or polynucleotide of claim 511, wherein said oligo- or polynucleotide is terminally ligated or attached to a polypeptide.
531. A composition comprising the oligo- or polynucleotide of claim 511, a polypeptide capable of forming a complex with Sig and a moiety which can be detected when such complex is formed.
532. The composition of claim 531, wherein said polypeptide comprises polylysine.
533. The composition of claim 531, wherein said polypeptide is selected from the group consisting of avidin, streptavidin and anti-hapten immunoglobulin.
534. The composition of claim 531, wherein said Sig is a ligand and said polypeptide is an antibody thereto.
535. The oligo- or polynucleotide of claim 511, wherein said Sig moiety is attached to a terminal nucleotide in said oligo- or polynucleotide.
536. The oligo- or polynucleotide of claim 535, wherein the sugar moiety of said terminal nucleotide has a hydrogen atom at the 2' position thereof.
537. The oligo- or polynucleotide of claim 535, wherein the sugar moiety of said terminal nucleotide has an oxygen atom at each of the 2' and 3' positions thereof.
538. The oligo- or polynucleotide of claim 511, comprising at least one deoxyribonucleotide.

539. An oligo- or polynucleotide which is complementary to a nucleic acid of interest or a portion thereof, said oligo- or polynucleotide comprising at least one modified nucleotide having the structural formula:



wherein BASE is a moiety selected from the group consisting of a pyrimidine, a purine and a deazapurine, or analog thereof, and wherein BASE is attached to the 1' position of the pentose ring from the N1 position when BASE is a pyrimidine or from the N9 position when BASE is a purine or a deazapurine;

wherein x is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;

wherein y is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate;


wherein z is selected from the group consisting of H—, HO—, a mono-phosphate, a di-phosphate and a tri-phosphate; and

wherein Sig is covalently attached directly or through a chemical linkage to at least one phosphate selected from the group consisting of x, y and z, and a combination thereof, said Sig comprising a non-radioactive label moiety which can be directly or indirectly detected when so attached to said phosphate or when said modified nucleotide is incorporated into said oligo- or polynucleotide, or when said oligo- or polynucleotide is hybridized to said complementary nucleic acid of interest or a portion thereof, provided that when said oligo- or polynucleotide is an oligoribonucleotide or a polyribonucleotide and when Sig is attached through a chemical linkage to a terminal PM at the 3' position of a terminal ribonucleotide, said chemical linkage is not obtained through a 2',3' vicinal oxidation of a 3' terminal ribonucleotide previously attached to said oligoribonucleotide or polyribonucleotide.

540. The oligo- or polynucleotide of claim 539, wherein said Sig is or renders the nucleotide or the oligo- or polynucleotide self-signaling or self-indicating or self-detecting.

541. The oligo- or polynucleotide of claim 539, wherein said Sig moiety comprises at least three carbon atoms.

542. The oligo- or polynucleotide of claim 539, wherein said covalent attachment is selected from the group consisting of



543. The oligo- or polynucleotide of claim 539, wherein said chemical linkage does not interfere substantially with the characteristic ability of Sig to form a detectable signal.

544. The oligo- or polynucleotide of claim 539, wherein said chemical linkage comprises a member selected from the group consisting of an olefinic bond at the α -position relative to the point of attachment to the nucleotide, a $-\text{CH}_2\text{NH}-$ moiety, or both.

545. The oligo- or polynucleotide of claim 539, wherein said chemical linkage comprises an allylamine group.

Electron microscopic visualization of tRNA genes with ferritin-avidin: biotin labels

Thomas R. Broker*, Lynne M. Angerer, Pauline H. Yen, N. Davis Hershey and Norman Davidson

Department of Chemistry, California Institute of Technology, Pasadena, CA 91125, and
*Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA

Received 31 October 1977

ABSTRACT

A method is described for indirect electron microscopic visualization and mapping of tRNA and other short transcripts hybridized to DNA. This method depends upon the attachment of the electron-dense protein ferritin to the RNA, the binding being mediated by the remarkably strong association of the egg white protein avidin with biotin. Biotin is covalently attached to the 3' end of tRNA using an $\text{NH}_2(\text{CH}_2)_5\text{NH}_2$ bridge. The tRNA-biotin adduct is hybridized to complementary DNA sequences present in a single stranded non-homology loop of a DNA:DNA heteroduplex. Avidin, covalently crosslinked to ferritin, is mixed with the heteroduplex and becomes bound to the hybridized tRNA-biotin. Observation of the DNA:RNA-biotin:avidin-ferritin complex by electron microscopy specifically and accurately reveals the position of the tRNA gene, with a frequency of labeling of approximately 50%.

INTRODUCTION

Electron microscopy has been used to study the organization of genes on chromosomes: (a) by analyzing substitution, deletion and insertion loops in heteroduplex structures prepared between DNA from related genomes (c.f., 1); (b) through cross-annealing identified segments of DNA (such as those present on transducing phages and bacterial F' episomes) (c.f., 2), and (c) by hybridizing purified RNA to complementary sequences in single-stranded (c.f., 3) or double-stranded DNA (c.f., 4). The success of these methods depends upon the existence of sufficiently long duplex regions for reliable discrimination between single and double strands. Methods of indirect visualization of short RNA molecules hybridized to DNA using single strand specific labels such as the T4 gene 32 protein (5) or the *E. coli* binding protein (6) are difficult to apply to very short RNA:DNA hybrid regions. Wu and Davidson

ABBREVIATIONS

NHS - N-hydroxysuccinimide; DMF - dimethylformamide; DMSO - dimethyl sulfoxide; DTT - dithiothreitol; GuHCl - guanidine hydrochloride; NaP - sodium phosphate buffer; NaBH_4 - sodium borohydride.

Nucleic Acids Research

(7) developed a labeling method using the electron-opaque protein ferritin covalently attached to the tRNA prior to the hybridization step. This technique has proven to be technically demanding.

We have developed an alternative method for attaching ferritin to RNA in an RNA:DNA hybrid. The RNA is covalently attached to the small molecule biotin and is then hybridized to the DNA. The protein avidin is covalently coupled to ferritin. The ferritin-avidin conjugate is then bound to the biotin-RNA:DNA hybrid by means of the strong non-covalent interaction between avidin and biotin.

In the present report we describe the chemical coupling and purification procedures in detail and our studies of the efficiency of electron microscopic mapping, using as a test system, the tRNA^{tyr} gene on the $\phi 80$ psu₃/ $\phi 80$ heteroduplex. The method gives reproducible results with gene labeling efficiencies near 50%. The tRNA genes of HeLa cell mitochondrial DNA have been mapped by this method (8). A further development of the same basic technique is described in the accompanying paper (9).

An alternative application of RNA-biotin:avidin technology for mapping genes has been described in a previous publication from this laboratory (10). *Drosophila* ribosomal RNA was coupled to biotin by a different method than the one described here and hybridized *in situ* to salivary gland chromosomes. This preparation was then treated with avidin coupled to polymethacrylate spheres; the hybrids with spheres attached could be visualized in the scanning electron microscope.

RATIONALE

The overall reaction scheme is illustrated in Fig. 1. The 2',3'-cis hydroxyl terminus of tRNA is oxidized by periodate to the dialdehyde and coupled to one of the amino groups of 1,5-diaminopentane by Schiff base formation and subsequent NaBH₄ reduction. Biotin is attached to the remaining amino group of the diamine by acylation with the NHS ester of biotin. The tRNA-biotin conjugate is hybridized to DNA containing the complementary gene sequence. Meanwhile, reactive bromoacetate groups are attached to ferritin and reactive thioacetate groups to avidin by NHS acylation reactions. These groups mediate the crosslinking of ferritin to avidin. The resulting conjugates are used to label the tRNA-biotin:DNA hybrid.

EXPERIMENTAL PROCEDURES

Commercial Materials: A list of purchased materials and their suppliers follows: *E. coli* tRNA, ¹⁴C-cysteine, ¹⁴C-N-ethyl maleimide, GuHCl and sucrose, (Schwarz-Mann); ³H-*E. coli* tRNA, (Miles); avidin and biotin, (Sigma); ¹⁴C-




Fig. 1. Overall reaction scheme for covalent attachment of biotin to RNA, avidin to ferritin, and for gene mapping.

Nucleic Acids Research

biotin, $^3\text{H-NaBH}_4$ (Amersham-Searle); dithiodiacetic acid, NHS, diaminopentane, (Aldrich); dicyclohexylcarbodiimide (MCB); NaBH_4 (Metal Hydrides, Inc.); Sepharose 2B and 4B (Pharmacia); DEAE-cellulose (BioRad); DMF, sodium iothalamate (Mallinckrodt); ethyl acetate (Baker).

Buffers: The buffers used in some of these experiments are indicated by the following abbreviations: 0.1 M NaCl, 0.01 M NaP, 0.001 M EDTA, pH 7.5 (1XSPE); 1M NaCl, 0.01 M NaP, pH 7.0 (HSB); 1M NaCl, 2M urea, 0.01 M NaP, pH 7.0 (HSUB). All phosphate buffers were prepared from NaH_2PO_4 with the pH adjusted with NaOH.

Specification and Assays: $^3\text{H-tRNA}$ (25,000 daltons MW; 1 mg/ml = 25 A_{260}) was monitored by optical density and by scintillation counting. Avidin (65,000 daltons MW; 1 mg/ml = 1.54 A_{282} (11)) was assayed by optical density and by its irreversible association with ^{14}C -biotin during exhaustive dialysis, sedimentation or chromatography (12, 13). Binding of ^{14}C -biotin is complete within 10 min when a 2- to 5-fold excess is added to avidin. One mg of avidin corresponds to 15.4 nmoles of the tetrameric protein, which bind 62 nmoles (15.1 μg) of biotin (11). Avidin conjugated to Sepharose or to ferritin probably binds less biotin, which makes assays only approximate. Heitzmann and Richards (14) obtained preparations of gluteraldehyde crosslinked ferritin-avidin with yields of biotin binding of approximately 50%. Holo ferritin (900,000 daltons MW; 1 mg/ml = 14.4 A_{280} or 1.54 A_{440} (7, 15)) was assayed by optical density.

NHS-biotin: The NHS ester of biotin was prepared by the method of Becker, Wilchek, and Katchalsky (16). To 12.4 ml of DMF containing 1 g of biotin and 0.475 g of NHS was added 0.85 g of dicyclohexylcarbodiimide. After 15 hr at 25°C , the reaction mixture was chilled to -20°C for 4.5 hr and the dicyclohexylurea precipitate removed by centrifugation. The supernatant was evaporated to dryness in a Buchler vacuum evaporator. The residue was washed with ethanol, dried and then recrystallized from isopropanol. The yield of NHS-biotin was 64%; its m.p. was $198-200^\circ\text{C}$. NHS- ^{14}C -biotin was synthesized similarly by incubating ^{14}C -biotin (50 μC), biotin (2.4 mg), NHS (1.1 mg) and dicyclohexylcarbodiimide (2.1 mg) in 50 μl DMF for 5.5 hr at 25°C . The resulting solution of ca. 0.2 M ^{14}C -NHS-biotin (Specific activity = 1.4×10^7 cpm/ μmole) was used without further purification. An alternate synthesis of NHS-biotin has been described (17).

NHS-dithiodiacetic acid: To a stirred solution of 1.82 g dithiodiacetic acid (0.01 mole) and 2.3 g NHS (0.02 mole) in 100 ml ethyl acetate was added 4.12 g dicyclohexylcarbodiimide (0.02 mole). The mixture was stirred at room

temperature for 2.5 hr. Dicyclohexylurea was removed by filtration and washed with 40 ml ethyl acetate. The combined filtrates were subjected to rotary evaporation at reduced pressure to yield a dark yellow oil. Several recrystallizations from methanol yielded white needles of the NHS ester with m.p. 131.5 - 135°C.

NHS-bromoacetic acid: The preparation of this ester has been described previously (18).

Synthesis of tRNA-biotin: *E. coli* K12 tRNA at concentrations ranging from 600 µg/ml to 10 mg/ml was incubated for 90 min at 37°C in 2M Tris, pH 8.2 to insure deacylation (19) and was then dialyzed against 0.05 M to 0.1 M sodium acetate, pH 4.7. One tenth volume of 1 M NaIO₄ freshly dissolved in water was added. After oxidation for 1 hr at 20°C in the dark, the tRNA was dialyzed at 4°C in the dark sequentially against 2 changes of 0.05 M sodium acetate, pH 5.1, 0.1 M NaCl, and two changes of 0.3 M sodium borate, pH 9.0 - 9.3 + 0.1 M NaCl. This solution was made 0.4 M in 1,5-diaminopentane, using a stock of the diamine that had been preadjusted to pH 9.3, and was then incubated for 45-90 min at 20°C in the dark. The resulting Schiff base was reduced with NaBH₄ using unlabeled or ³H-labeled reagent: (i) unlabeled NaBH₄, freshly dissolved in water, was added four times at 30 min intervals, resulting in increments of 0.025 M to 0.1 M BH₄⁻ and incubation was continued for a total of 3 hr at 20°C; (ii) ³H-NaBH₄ (1.28 M and 490 µC/µmole in 1 N NaOH) was added to the Schiff base in 15X molar excess and incubated for 1.5 hr at 0°C, then 2 hr at 20°C. The reduction was then driven to completion by the further addition of unlabeled NaBH₄ as described above. Residual NaBH₄ was quenched by adjustment to pH 5 - 5.5 with 4M sodium acetate, pH 5. The tRNA-amine was dialyzed extensively first against 0.1 M NaCl, 0.01 M - 0.05 M NaP, pH 6.8, 0.001 M EDTA and then against 40% DMF, 0.03 M NaCl, 0.05 M NaP, pH 6.8. NHS-biotin was dissolved in DMF and added to the tRNA-amine (0.5-5 mg/ml) to a final concentration of 20 mM NHS-biotin and about 50% DMF. The reaction was carried out for 12-16 hr at 20°C. Excess NHS-biotin was removed by dialysis against 40% DMF, 0.15 M NaCl, 0.05 M NaP, pH 7.0 and then against 1XSPE. Some preparations of tRNA-biotin were passed through G-25 Sephadex to remove any residual free biotin. The RNA in the excluded volume was precipitated in 70% ethanol for 24 hrs at -20°C and then redissolved in HSB in preparation for chromatography on avidin-Sepharose.

Preparation of Avidin-Sepharose: Avidin was coupled to Sepharose by a procedure similar to those described previously (20, 21, 22). Sepharose 4B (30 µm-200 µm beads) was washed free of sodium azide and was deaerated under

Nucleic Acids Research

vacuum. 20 ml of Sepharose slurry was suspended in 20 ml water and adjusted to pH 11 with NaOH. 2-4 gm cyanogen bromide, dissolved in 1-2 ml dioxane, was added dropwise over a 3 min period to the Sepharose with gentle mixing. In some preparations, the activation was done at 0°C, in others at 20°C; in either case, the reaction was continued for 10 min while maintaining pH 10.5 - 11.5 with additions of 2 N NaOH. The slurry was poured into a fritted glass filter and washed with about 200 ml 0.1 M sodium carbonate pH 9.0, 0°C. The cake was resuspended in an equal volume of the same buffer. A solution containing 20 mg avidin was added and incubated with the activated Sepharose for 12-24 hr at 4°C. The activated Sepharose was quenched with additional incubation with 0.05 M 2-aminoethanol for 1 hr at 20°C. The avidin-Sepharose was poured into a chromatographic column and successively eluted with 2 vol of HSB, 2 vol of HSUB, 3 vol of 6M GuHCl, pH 2.5, and 5 vol of HSB containing 1 mM EDTA, in which it was stored until use. The effective capacity of the avidin-Sepharose was determined by measuring the amount of ^{14}C -biotin which could be bound to 1 ml of avidin-Sepharose in HSB and eluted with 6M GuHCl. The procedure just described was found to give 5-15 nmole biotin binding sites per ml of packed bed. An alternative synthesis of avidin-Sepharose has been described recently (23).

To facilitate recovery of tRNA-biotin from avidin-Sepharose, the strongest binding sites on the adsorbent were presaturated with free biotin as follows. Columns of avidin-Sepharose were washed with HSB containing a several fold excess of biotin. They were then washed successively as described above with HSB, HSUB and GuHCl, pH 2.5, to liberate biotin from the weaker binding sites. The columns were regenerated in HSB.

Purification of tRNA-biotin on avidin-Sepharose: tRNA-biotin was purified from residual tRNA and tRNA-amine by selective retention on and elution from a 5 ml column of avidin-Sepharose. The sample was loaded in HSB, and the column was washed with 5 vol of the loading buffer. tRNA without biotin does not bind at this ionic strength. The column was then washed with HSUB to eliminate any tRNA retained by nonspecific hydrophobic interactions. This treatment does not disrupt any but the weakest avidin-biotin interactions. The tRNA-biotin was eluted with 6M GuHCl, pH 2.5, identified by scintillation counting and dialyzed against HSB. The avidin-Sepharose columns were regenerated by washing with 5 vol HSB and could be reused at least several times.

DEAE-cellulose chromatography of tRNA-biotin: tRNA-biotin was chromatographed on DEAE-cellulose columns in 7M urea, 10 mM Tris, pH 8.0, and eluted

with a 0.25 M to 0.5 M NaCl gradient according to the method of Penswick and Holley (24). See legend to Fig. 3 for additional experimental details.

Isolation of Ferritin: Ferritin was purified from horse spleen according to a procedure modified from Granick (25). Three or four horse spleens weighing ca. one kg each were minced in a meat grinder and ferritin was extracted from the residue in 5 l of 80°C water for 10 min. After cooling to 5-10°C in an ice-salt bath, the mixture was filtered through cheesecloth. The filtrate was centrifuged 15 min at 1500 x g. The ferritin was then precipitated by adding solid ammonium sulfate to 35% (w/v). After an overnight incubation at 4°C, the precipitate was collected and redissolved in 2% ammonium sulfate. Insoluble material was removed by centrifugation and the supernatant was made 4% CdSO₄, by adding ½ vol of 20% Cd SO₄, pH 5.8. Ferritin crystals were collected after 3 hr at 4°C, dissolved in 2% ammonium sulfate and the crystallization procedure repeated 4 or 5 times. Ferritin was precipitated twice with 50% ammonium sulphate, dialyzed extensively versus 50 mM NaP, pH 7.0, and sterilized by passage through Millipore HAWP filters (0.45 µm). Approximately 1 g of ferritin was obtained, which was stored either as an aqueous solution at 2°C or in 50% glycerol, 25 mM NaP, pH 7.0, at -20°C.

Synthesis and purification of ferritin-avidin conjugates: Ferritin (20 mg/ml) in 0.3 M potassium borate, pH 9.3, was bromoacetylated by gentle mixing with about 0.06 vol of a 10 mg/ml solution of the NHS ester of bromoacetic acid in DMSO. After reaction for 1 hr at room temperature, the sample was dialyzed against 1XSPE. The extent of modification was determined by reaction with ¹⁴C-cysteine and measurement of the nondialyzable radioactivity.

The addition of sulfhydryl groups to avidin was accomplished with the same chemistry as outlined above. To a solution of avidin (2.0 - 2.4 mg/ml) in 0.3 M potassium borate, pH 9.3, NHS-dithiodiacetic acid dissolved in DMF was added to give a final ester concentration of 1-3 mg/ml. After reaction for several hr at room temperature, sulfhydryl groups were liberated by treatment for 20 min at 37°C with DTT at a concentration of 12-18 mg/ml. Excess ester and DTT were removed from the reaction mixture by dialysis against 1XSPE under argon. The number of SH groups/avidin was assayed by determining the nondialyzable binding of ¹⁴C-N-ethylmaleimide.

Ferritin-(CCH₂Br)_n was mixed with avidin-(CCH₂SH)_m in 0.3 M potassium borate buffer, pH 9.3, under argon. The ferritin concentration was 8.2 - 10.4 µM and the avidin concentration was 21-26 µM. After 2 hr at room temperature, the coupling reaction was quenched by adding 2-aminoethanol (16 M), pH 9.0, to a final concentration of 0.38 M. The mixture was then

Nucleic Acids Research

layered on 5-50% sucrose gradients containing HSB + 1mM EDTA built on a 60% sucrose cushion. Ferritin-avidin conjugates and free ferritin were separated from free avidin by two cycles of velocity sedimentation at 36,000 rpm for 7 hr in SW 50.1 rotor at -2°C (or at 40,000 rpm for 4 hr at 0°C).

Hybridization of tRNA-biotin to DNA - the $\phi 80$ psu_3^- system: Phage stocks were prepared as described previously (7). 1.0×10^{10} phage particles of $\phi 80$ wild type and of $\phi 80$ psu_3^- (with a tRNA^{tyr} gene) (each sufficient to contribute 0.5 μg DNA) were diluted into 20 μl of 0.2 M EDTA, pH 8.5, and incubated for 10 min at 20°C . 40 μl H_2O and 20 μl of 1M NaOH were added and incubation was continued for 10 min. The solution was neutralized with 30 μl of 2.5 M Tris HCl, pH 3.5. *E. coli* tRNA-biotin (3-50 μg) was added and the solution was dialyzed versus 40% formamide, 0.3 M NaCl, 0.1 M Tris, 0.001 M EDTA, pH 8.0, for 30-60 min at 40°C . After hybridization, excess tRNA-biotin was removed from the mixture by passage over a 3 ml Sepharose 2B column equilibrated with 1XSPE. The excluded volume was collected and concentrated under vacuum 5- to 7-fold to 50-75 μl .

Labeling DNA:DNA:tRNA-biotin hybrids with ferritin-avidin: Nearly equal volumes of ferritin-avidin and the hybrids were mixed to give a ferritin concentration of 0.1-1 mg/ml (about 10^{-7} - 10^{-6}M), the equivalent of a 1000-10,000-fold excess over the hybridized tRNA-biotin. To allow conjugation, samples were incubated for at least 16 hr at 20°C . Excess ferritin-avidin was removed by centrifuging the mixture through a 5.4 ml gradient of sodium iothalamate ($\rho = 1.2-1.4$), buffered with 0.1 M Tris, 10 mM EDTA, pH 8.0, for at least 8 hr at 35,000 rpm at 15°C in an SW 50.1 rotor. Since the density of DNA in sodium iothalamate is 1.14 (26), while that of ferritin is estimated to be 1.6 - 1.8 (15), ferritin-labeled hybrids can be separated from excess ferritin-avidin. The DNA-containing fractions (0.2 - 0.6 ml from the top of the gradient) were collected manually from the top, dialyzed against 0.8 M NaCl, 0.1 M Tris, 0.01 M EDTA, pH 8.5, and then against 0.2 M Tris, 0.02 M EDTA, pH 8.5. In some cases the samples were concentrated 3- 4-fold in a vacuum dessicator and redialyzed against 0.2 M Tris, 0.02 M EDTA, pH 8.5, in preparation for electron microscopy.

Electron microscopy: The electron microscopic procedures used here are described in more detail in Davis *et al.* (1). The spreading solution contained 50% formamide, 0.1 M Tris, 0.01 M EDTA, pH 8.5, and 50 $\mu\text{g}/\text{ml}$ cytochrome-c. Depending on the fraction taken from the iothalamate gradient and depending on the experiment, the final DNA concentration ranged from 0.01 - 0.25 $\mu\text{g}/\text{ml}$. The hypophase consisted of 15% formamide, 0.01 M Tris, 0.001 M

EDTA, pH 8.5. The DNA was picked up on parlodion-coated copper grids, stained with 10^{-4} M uranyl acetate and shadowed with 3 - 3.5 cm of platinum palladium (80:20) wire (0.008 gauge) at an angle of 1:9 radians.

Heteroduplex molecules were examined to determine whether they had ferritin labels at the appropriate location on the $\phi 80$ psu_3 strand based on previous mapping (7). Labeled molecules were photographed on 35 mm film at a magnification of 4620 and traced with a Hewlett-Packard digitizer to confirm the location. The percentage of labeling was calculated as the number of correctly labeled molecules divided by one-half the number of heteroduplexes observed (since in half the heteroduplexes the $\phi 80$ psu_3 strand is not the complement of tRNA^{tyr}).

RESULTS

Synthesis of tRNA-biotin: The synthesis of *E. coli* tRNA-biotin was carried out as described in Experimental Procedures. The oxidation reaction was essentially complete as assayed by nondialyzable binding of ^{14}C -isonicotinic hydrazide. Addition of diaminopentane to form a Schiff base was not quantitative and the yield was highly variable among experiments. In previous studies in which oxidized tRNA was treated with cystamine and the product was reduced with DTT and assayed for SH groups with ^{14}C -N-ethylmaleimide, the yields of tRNA-amine varied from 20-80% (7 and our unpublished observations). Similarly, in these experiments, the yield of tRNA-biotin varied from 20-80% as determined either by using ^{14}C -biotin or by binding the reaction mixtures to avidin-Sepharose columns. Since the acylation of primary amines with NHS esters is known to be very efficient, we believe that the variability in yields of tRNA-biotin results from incomplete formation of the Schiff base and/or of its reduction by NaBH_4 . We show below that the procedure causes little if any degradation of the tRNA.

tRNA-biotin conjugates were purified from unmodified tRNA on avidin-Sepharose columns prewashed to remove uncrosslinked avidin subunits and preloaded with biotin to mask the strong binding sites as described in Experimental Procedures. The recovery of tRNA from these columns is usually about 95%. An example of the elution profile is illustrated in Fig. 2. In the top panel, the first passage of tRNA-biotin is shown. In this particular preparation, 50% of the A_{260} bound to the column in 1M NaCl and was eluted in 6M GuHCl, pH 2.5. The bottom panel of Fig. 2 shows that greater than 95% of this material bound on repassage, indicating that the tRNA was not degraded as a result of exposure to the strongly denaturing elution buffer. Further, the excellent rebinding of the tRNA-biotin conjugates suggests that




Fig. 2. Affinity chromatography of tRNA-biotin on Avidin-Sepharose. Top: 900 μ g (32 nmoles) of tRNA in HSB was loaded on a 5 ml column of avidin-Sepharose. The total biotin binding capacity of the column was 45 nmoles. Twenty-five ml each of HSB, HSUB and 6 M GuHCl, pH 2.5, were passed through the column. One ml fractions were collected. Bottom: A portion of the material which bound to avidin-Sepharose was rechromatographed on the same column using exactly the same procedure.

it is unlikely that avidin subunits were released during the first pass and became attached to tRNA-biotin.

In one experiment, tRNA-amine was acylated with NHS- 14 C-biotin (Sp. act. = 1.4×10^7 cpm/ μ mole). After purification on avidin-Sepharose, the specific activity of the tRNA-biotin conjugates was 6.2×10^2 cpm/ μ g, indicating that the biotin:tRNA ratio was 1.11:1. Assuming that acylation occurred only at the 3' termini and the tRNA was not degraded, this ratio indicates that the tRNA-biotin preparation is quite pure.

In order to check that the tRNA-biotin was not degraded during the derivatization and purification procedures, it was chromatographed on DEAE-cellulose

in 7M urea, 10 mM Tris, pH 8.0 and eluted with a linear NaCl gradient from 0.25M-0.5M following the procedure of Penswick and Holley (24). According to their results and ours, intact tRNA elutes at ca. 0.38 M NaCl while half size molecules elute at lower ionic strengths (0.31M-0.35M). As shown in Fig. 3, 98% of the tRNA-biotin elutes in a single peak at about 0.38 M indicating that most of the molecules are still full size, or nearly so, and therefore long enough to form stable hybrids. These results also indicate that avidin subunits do not leak from the column and bind to tRNA-biotin. If avidin ($pI = 10.5$) were bound to tRNA-biotin, the elution profile of such complexes which are stable in 7M urea (27) would be different from tRNA alone. Other RNA-biotin samples were analyzed by electrophoresis on 6M urea-15% polyacrylamide gels. No degradation could be detected when the electrophoresis profiles of RNA-biotin and unmodified RNA were compared.

Ferritin-avidin Coupling. Table I shows that, in four separate preparations of bromoacetylated ferritin, between 10 and 21 moles of active bromide were added per mole of ferritin as assayed by the non-dialyzable binding of ^{14}C -cysteine (see footnote a of Table I for details of assay). Attachment of SH groups to avidin was carried out as described in Experimental




Fig. 3. Chromatography of tRNA-biotin on DEAE-cellulose in 7M urea. 360 μ g of tRNA-biotin was dissolved in 7M urea, 10 mM Tris, pH 8.0, 0.25M NaCl and loaded on a 2.3 ml column of DEAE-cellulose. The column was developed with a 50 ml gradient from 0.25-0.5 M NaCl. 0.7 ml fractions were collected.

Table I
Synthesis of Bromoacetylated Ferritin and Avidin-SH

Experiment Number	Input Molar Ratio		Reaction Time (hours)	+ DTT	(a) ^{14}C cysteine bound ferritin	Molar ratios		(c) ^{14}C biotin avidin
	NHS ester ferritin	NHS ester avidin				(b) ^{14}C NEM avidin		
1	100	-	1	-	-	-	-	-
2	120	-	2.5	-	16.3	-	-	-
2a	10	-	-	-	20.8	-	-	-
3	105	-	-	-	0.3	-	-	-
4	95	-	2	-	10.1	-	-	-
					12.6	-	-	-
1	-	100	1	+	-	-	-	-
2	-	290	1	+	-	15.0	3.2	-
3	-	100	2	+	-	10.8	1.9	-
4a	-	100	2	+	-	5.5	2.0	-
4b	-	0	0	+	-	5.8	4.0	-
4c	-	0	0	-	-	1.4	3.6	-
					-	-	3.7	-

(a) Bromoacetylated ferritin was assayed by incubating 10 μg of ferritin with 25 μM of ^{14}C cysteine for 10 min at 37°C.

- (a) Bromoacetylated ferritin was assayed by incubating 10 to 20 picomoles of either modified or unmodified ferritin with 25 nmoles of ^{14}C cysteine (Sp. Act. = 15 C/mole) in 50 μl of 0.3 M potassium borate, pH 9.3 under argon for 2 hrs at 25°C. Excess cysteine was removed by dialysis vs. LXSE, 1mM DTT.
- (b) Avidin-SH was assayed by incubating 0.7 to 0.9 nmoles of either modified or unmodified avidin with 50 nmoles of ^{14}C N-ethylmaleimide (NEM) (Sp. act. = 2.5 C/mole) in 200 μl of LXSE, pH 7.5, for 2 hrs at 25°C. Excess NEM was removed by dialysis versus LXSE.
- (c) Biotin binding was determined by incubating 0.7 to 0.9 nmoles of either modified or unmodified avidin with 30 nmoles of ^{14}C biotin (Sp. act. = 45 C/mole) in 100 μl of LXSE for 1 hr at 25°C. Excess biotin was removed by dialysis versus LXSE.

Procedures. After liberation of the sulfhydryl groups with DTT, the preparations were dialyzed extensively in oxygen-free buffer and assayed with ^{14}C -N-ethylmaleimide (see footnote b of Table I for details of assay). Although the number of sulfhydryl groups added was somewhat variable among different experiments, all preparations were still capable of binding biotin. In some preparations, no loss of biotin binding was observed (see footnote c, Table I for assay). All of these preparations were able to couple to bromoacetylated ferritin with roughly similar efficiencies.

Modified ferritin and avidin were coupled and purified as described in Experimental Procedures. After the first sucrose gradient sedimentation, 70% of the total biotin binding activity was recovered; the remainder apparently pelleted in insoluble ferritin-avidin aggregates. 65% of the recovered biotin binding activity was associated with the ferritin band in the lower third of the gradient while the remaining 35% was found at the top of the gradient with uncoupled avidin-SH. The fractions containing ferritin were pooled, dialyzed and run on a second identical sucrose gradient and the biotin binding activity of various portions of the gradient determined. 99.9% of the biotin binding activity sedimented with the ferritin band. When

several fractions within the ferritin band were assayed with ^{14}C -biotin, the number of moles of biotin bound per mole of ferritin varied from 2.5 to 4.8, values which correspond to the slower and faster sedimenting ferritin-avidin conjugates, respectively. Electron microscopic examination of these fractions showed that the faster sedimenting material contained more aggregates while the slower sedimenting material was almost entirely ferritin monomers. The monomer fractions were used for the gene labeling experiments. We estimate, both from the recovery of biotin binding activity in these gradients and the number of moles of biotin bound per mole of ferritin, that an average of one to two moles of avidin have been coupled to each mole of ferritin.

The following experiment was done to test whether these ferritin-avidin conjugates could bind tRNA-biotin. Equimolar amounts of tRNA- ^{14}C -biotin (0.65 nmoles, 6900 cpm) and ferritin-avidin (0.65 nmoles ferritin, 2.6 nmoles biotin binding sites) were incubated in 1 x SPE for 24 hours at room temperature. In an identical control reaction, 0.8 nmoles of ^3H tRNA (3.47×10^4 cpm) were incubated with 0.65 nmoles of ferritin-avidin. The reaction mixtures were sedimented 4 hrs at 40,000 rpm at 0°C in the SW 50.1 rotor through a 5-20% sucrose gradient built on a 0.5 ml 60% sucrose cushion containing 2XSPE. As shown in Fig. 4, 100% of the counts in the control reaction (●-●), were recovered and sedimented near the top of the tube while in the tRNA-biotin:avidin-ferritin reaction (x-x), 91.8% of the counts were found associated with the ferritin band in the bottom two fractions of the gradient. Since no absorbance due to tRNA ($\Delta\text{-}\Delta$) was detected at the top of this gradient, we conclude that the ^{14}C counts at the bottom of the gradient represent the binding of at least 90% of the tRNA-biotin in the reaction. Other experiments confirm that our preparations of ferritin-avidin contain little if any ribonuclease activity, since ^3H -tRNA incubated with ferritin-avidin as in the control experiment described above remains full length as assayed in denaturing polyacrylamide gels (data not shown).

Gene Mapping Studies. In order to test the efficiency of labeling DNA: tRNA-biotin hybrids with ferritin-avidin, we have used the heteroduplex formed between the bacteriophage DNAs of $\phi 80$ wild type and $\phi 80$ psu_3^- . $\phi 80$ psu_3^- contains a 3.2 kb sequence of *E. coli* DNA carrying one gene for tyrosine tRNA. The position of this gene in the $\phi 80$ wild type/ $\phi 80$ psu_3^- heteroduplex was mapped in previous studies (7). The hybridization conditions and methods for purifying the hybrids are described in detail in Experimental Procedures. Fig. 5a is an electron micrograph of a heteroduplex labeled with ferritin




Fig. 4. 5-20% Sucrose gradient sedimentation of reaction mixtures containing either ^3H -tRNA + ferritin-avidin (\bullet - \bullet) or tRNA- ^{14}C -biotin + ferritin-avidin (\times - \times). The A_{260} due to tRNA-biotin is also indicated (Δ - Δ). Ferritin sedimented to the bottom of the gradient as indicated by the arrow. Note that the concentration of tRNA at the bottom of the gradient cannot be measured by A_{260} because of the large absorbance by ferritin at this wavelength.

in the proper position. A histogram of the distribution of labels is presented in Fig. 5b. In this experiment, 106 heteroduplexes were scored for labels. Thirty three heteroduplexes contained ferritin bound to the tRNA gene which is located 1200 nucleotides to the right of the substitution junction at the λ att site. One ferritin was judged to be attached non-specifically. Four ferritins were bound at a position 200 nucleotides to the right of the main peak and, therefore, were not attached to the tRNA^{tyr} gene. This non-random distribution may or may not reflect some weak interaction between the tRNA and DNA at this point.

Several labeling experiments were performed by three different investigators. The combined data are listed in Table II. In these experiments, the hybridizations were carried out over a 25-fold range in rot (rot = (RNA concentration in nucleotide/moles/l) \times (time in sec.)). O. Uhlenbeck and his co-workers (personal communication) have determined that the $\text{rot}_{1/2}$ for a pure tRNA under the same conditions is 3×10^{-4} . The lowest rot used based on total tRNA concentration was 0.32, or a rot of 0.016 for tRNA^{tyr}, if this species constitutes about 1/20th of the total, and thus 50 times greater than the required $\text{rot}_{1/2}$. It is clear that there is no correlation between the rot achieved during




Fig. 5. (a) Electron micrograph of $\phi 80$ wild type/ $\phi 80$ psu_3^- heteroduplex. The arrows indicate the positions of the ferritin label and the ϕatt site. (b) Histogram of distribution of ferritin labels on the 3.2 kb bacterial segment of $\phi 80$ psu_3^- , measured to the right from the att junction near the center of the molecule (7). The att site and the fork at the other end of the substitution loop are 23.8 and 19.3 kb from the left and right ends of the heteroduplex, respectively (5); therefore, they are readily distinguished.

Table II
Efficiency of Gene Labeling

Experiment Number	(a) $tRNA^{tyr}$ rot	Ferritin-avidin $\mu g/ml$	per gene	Labeling time	Number Heteroduplexes	Number genes labeled	(b) % genes labeled
1	1.6×10^{-2}	259	9400	17	42	9	22
2	3.4×10^{-2}	1000	5300	18	25	6	48
3	10×10^{-2}	73	4900	16	106	33	62
4a	42×10^{-2}	16	140	8	25	0	0
4b	42×10^{-2}	9.0	790	8	25	0	0
4c	42×10^{-2}	161	14000	70	25	5	40
4d	42×10^{-2}	211	18500	70	27	8	59

(a) The concentration $tRNA^{tyr}$ is assumed to be equal to 1/20 of the mass of tRNA.

(b) % genes labeled = $\frac{\text{number of labels}}{(\frac{1}{2}) (\text{number of heteroduplexes})}$

the hybridization and the labeling efficiency. The concentration of ferritin-avidin and the ferritin-avidin:gene ratio were also varied. Only in experiments 4a and 4b (Table II) in which both the ferritin-avidin concentration and ferritin-avidin/gene ratio were low was no labeling observed. In the

other experiments the ferritin concentrations were considerably higher. However, aside from this observation, no clear relationship exists between the gene labeling efficiency and either the concentration or molar excess of ferritin-avidin in the labeling reaction.

Discussion and Experimental Precautions. Several experimental precautions should be observed to maximize the efficiency of this gene labeling procedure. Also some potential side reactions may influence the success of the technique.

Preparations of tRNA may be depleted in certain labile species such as tRNA^{trp} and should be tested for amino acid acceptance by the species to be mapped. Obviously, the existence of isoacceptors reduces the value of this assay unless tRNA samples are fractionated. tRNA preparations may be contaminated with 5S and other small RNAs (and vice versa). Usually these possibilities can be tested by appropriate controls.

tRNA is treated with 2M Tris buffer at pH 8.2 to deacylate any residual amino acids (19); thereafter amine buffers must be absent until the chemical linkage of biotin to the RNA is complete. Excess small molecule reagents such as Tris HCl, NaIO₄, alkane diamines, and NHS-biotin are preferably removed by dialysis or by gel filtration. (Ethanol precipitation of the tRNA does not eliminate all traces of these reagents.) To reduce the possibility of side reactions, solvents and pH are not altered until the reagents are removed. Oxidized tRNA is particularly sensitive to amine-catalyzed beta-elimination of the 3'-terminal nucleotide (28).

Reactions and incubations should be performed in the dark. For instance, periodate-oxidized tRNA dialdehyde is sensitive to photooxidation to the carboxylic acid. The alkane diamines appear to be light-sensitive and should be stored in the dark. The tryptophan residues at the active site of avidin are sensitive to photooxidation in the presence of Fe³⁺ (12), which is a perpetual contaminant once avidin and ferritin have been mixed.

The formation of the Schiff base between oxidized tRNA and the diamine must be driven by as large an excess of amine as is practicable. Diamines shorter than C5 do not provide a linker arm long enough to allow biotin to extend sufficiently far from the macromolecule carrier surface to penetrate the avidin binding sites (29). Diamines longer than about C7 are not sufficiently soluble in water to allow the Schiff base formation to be driven by the necessary concentration excess. Borohydride reduction of the Schiff base presents the opportunity for introduction of a 3'-terminal tritium label from ³H-NaBH₄, allowing the RNA to be traced subsequently during

chromatography and the stability of tRNA-biotin:avidin-ferritin conjugates to be measured.

Several side reactions may cleave certain tRNA species during the modification and purification steps. In particular, the NaBH_4 reduction step modifies 7-methylguanosine and dihydrouridine residues so that adjacent phosphodiester linkages are sensitive to cleavage at low pH (30, 31). *E. coli* tRNA^{tyr} contains a 7-methylguanosine at position 17 from the 5' end. Cleavage at this point would leave a fragment of tRNA extending 68 nucleotides from the biotin-labeled 3' end. This fragment is of sufficient length to chromatograph and hybridize like intact tRNA in the tests described above. Thus, we do not have a critical test to determine whether the present procedure causes significant cleavage at 7-methylguanosine residues. Periodate oxidation probably converts thiouridine to uridine which is not harmful (32). Whether or not the reduction by NaBH_4 of dihydrouridine (32) is deleterious for the present mapping procedure is not known.

Avidin, and particularly avidin-biotin complexes are extraordinarily stable and can withstand heat, pH extremes (2 - 12), urea and 50% formamide (12, 27, 33). The avidin subunits can be separated and the complexes can be denatured in the presence of 6M GuHCl, pH 2.5 or lower (36, 22). Subunit renaturation and reassociation and avidin-biotin binding are freely reversible upon removal of the GuHCl as long as thiol reagents (e.g., DTT) are not present during the denaturation of the avidin (35).

Avidin-biotin complexes are far more stable to subunit dissociation and to denaturation than is free avidin (35). Thus, before exposure to biotin freshly made avidin-Sepharose must be washed with GuHCl, pH 2.5, to remove avidin subunits which were not covalently cross-linked to the matrix. Avidin subunits retain a substantial affinity for biotin (37, 22). Avidin and avidin subunits have a spectrum of biotin affinity constants and it is impractical to reverse the tightest binding (22). Therefore, Sepharose-avidin subunit columns should be exposed first to free biotin to saturate all sites and then eluted with GuHCl, pH 2.5, to free all but the strongest biotin binding sites. These pretreatments will allow good recoveries of tRNA-biotin from the columns and will eliminate any uncrosslinked avidin subunits that might otherwise contaminate the tRNA-biotin upon subsequent elution. Avidin-Sepharose columns are run in the presence of 1 M NaCl at all times to minimize electrostatic interactions between nucleic acids and the very basic avidin.

Ferritin is a somewhat unstable protein and should be freshly recrystal-

Nucleic Acids Research

lized before use. It does not withstand freezing or exposure to high salt (e.g., 6 M CsCl). We have noticed that it tends to denature upon prolonged exposure to formamide. Extensive treatment with EDTA may cause substantial release of Fe^{+3} , which may adversely affect avidin (12), nucleic acids and R-SH + R-Br reactions. The free iron concentration should be minimized by dialysis of ferritin solutions shortly before reaction or conjugation steps. To insure the absence of apoferritin and unbound avidin, ferritin-avidin preparations should be sedimented through sucrose gradients immediately prior to use. To prevent pelleting the ferritin-avidin, which is then difficult to resuspend, a cushion of 60% sucrose is used at the bottom of the gradient. The gradient is run at approximately 0 to -2°C to increase its viscosity.

Since labeling of DNA:RNA-biotin should be done at high ferritin-avidin concentrations, it is necessary that ferritin-avidin preparations be absolutely free of unbound avidin. The long incubation opens the possibility for nuclease or protease action and compels care in sterile handling throughout preparation of the sample.

Tolerable background concentrations of ferritin can be achieved if the complexes are prepared for electron microscopy at no more than 1.0 $\mu\text{g}/\text{ml}$ free ferritin-avidin in the hyperphase spreading solutions. Separation of excess ferritin-avidin from hybrids on sodium iothalamate gradients achieves this level of purity.

Ferritin can be confused easily with coarse platinum shadow. Best definition of the label is achieved if a shutter is imposed between the metal filament and the specimen grids during the initial phase of melting and if subsequent evaporation is done just above the melting temperature of the Pt or Pt-Pd. Very light shadowing is required.

FURTHER DISCUSSION

Unlike studies of the distribution of targets such as proteins in surfaces, identification of single features such as genes or proteins on linear chromosomes requires a high labeling efficiency as well as low backgrounds.

The overall efficiency of labeling achieved here is about 40-50%. The percentage of the genes labeled depends upon the tRNA^{tyr} :DNA hybridization and the ferritin-avidin binding efficiencies. It seems plausible that attachment of biotin to tRNA does not significantly alter its rate of hybridization or the stability of the hybrid; therefore, saturation of the gene should be possible at a sufficiently high rot. It is probable that the overall efficiency of this technique is limited by our ability to detect labeled hybrids and by those factors which influence the association of ferritin-

avidin conjugates with biotin-containing hybrids. Such factors include: (1) the stability of ferritin (if iron is lost from ferritin during the course of the experiment, then apoferritin-avidin complexes will be produced which are not visible in the electron microscope); (2) the stability of ferritin-avidin conjugates (traces of free avidin or avidin subunits may react faster with tRNA-biotin hybrids than ferritin-avidin does); (3) the purity of the tRNA-biotin preparation; (4) the stability of the tRNA-biotin linkage; and (5) steric factors which affect the association constants and/or the rates of reaction of ferritin-avidin with biotin-containing hybrids.

We believe that the first three of these factors are not the main cause of the limited labeling efficiency. First, we have used only ferritin-avidin conjugates which have been selected for high density by two cycles of sucrose gradient sedimentation. Second, after the second cycle, we detect less than 0.1% of the total biotin binding activity not associated with ferritin band. Finally, we have shown that tRNA-biotin derivatives are at least 95% pure by repassage through avidin-Sepharose. These derivatives contain an equimolar ratio of biotin to tRNA. The RNA remains full size or nearly full size during modification.

Earlier experiments have shown that the tRNA-amine linkage is stable to our hybridization conditions (7). This result is confirmed with tRNA-biotin by the observation that tRNA-biotin first incubated under hybridization conditions binds ferritin-avidin as extensively as unincubated control samples. Thus, we expect that the tRNA-biotin linkage is stable during our experiments.

Some steric problem which interferes with the avidin reaction might contribute to suboptimal labeling efficiencies. We have found that very high concentrations of ferritin-avidin are required to drive the labeling reaction although much lower concentrations are sufficient to bind unhybridized tRNA-biotin. This observation may be explained by considering the following ideas. First, tRNA-biotin may have a less favorable association with ferritin-avidin than does free biotin. If the linker bridge between biotin and the macro-molecule to which it is coupled is not at least 7 or 8 bonds, the equilibrium constant will increase markedly (36, 29). Second, while the chemistry used to modify avidin for subsequent reaction with ferritin does not significantly reduce the number of biotin binding sites, the effect on the equilibrium constant is not known. Finally the concentration of avidin:biotin complex in the spreading solution is very low, about 10^{-11} M. Therefore, the conjugate must be exceptionally stable. With equilibrium binding constants much greater than 10^{-13} M, substantial dissociation would occur in the

time necessary for removal of excess ferritin-avidin or even for spreading the hyperphase during electron microscopic grid preparation. The equilibrium constant for free avidin and biotin at pH 7 in high salt (0.1 M NaCl) is about 10^{-15} - 10^{-13} M (13, 22). If the tRNA-biotin:avidin-ferritin association is weaker by several orders of magnitude, perhaps only a small fraction of ferritin-avidin conjugates are capable of forming stable associations under our labeling and spreading conditions.

With this caveat, the avidin-biotin affinity pair satisfies all requirements for speed and stability of association, for availability of materials, for ease of attachment to a wide variety of macromolecules and solid supports, and for convenient assay. All necessary reactions that might affect the integrity of biological materials can be done between pH 5 and 9 and at temperatures no higher than 37°C in aqueous or compatible mixed solvents. The reactions are versatile and strategies can be devised and executed in which either avidin or biotin can be coupled to any of the components which must be conjugated. For example, in addition to gene mapping studies, the avidin:biotin linkage has recently been used to enrich the 18s and 28s ribosomal genes (38, 39) and the 5s ribosomal genes from whole *Drosophila* DNA (9).

In contrast to a method previously described (7), in which ferritin was conjugated directly to tRNA before its hybridization to DNA, the scheme reported here allows the label to be added to established DNA:tRNA-biotin hybrids. In principle, this should allow more efficient nucleic acid hybridization and higher labeling efficiencies. Furthermore, the ferritin label is added after the hybridization in a nondenaturing solvent which preserves ferritin structure. In practice, the maximum efficiencies of both methods are about 60%, but the ease of handling, the speed and the reproducibility in the hands of many workers are higher with the avidin-biotin mediated linkage than with the chemical linkage.

It is important to emphasize that the labeling efficiencies achieved here allow analysis only of defined segments of DNA. Specifically, this means that a fixed point or marker is needed from which to map the labeled genes. Such a reference point could be a restriction endonuclease cleavage site, a substitution or deletion loop in a heteroduplex, a secondary structure feature in the DNA or a long duplex region formed by hybridizing specific RNA or DNA probes (8, 40). When such systems are studied with this technique, it is possible in a single experiment to obtain a gene map with a resolution of several hundred nucleotides.

ACKNOWLEDGMENTS

We gratefully acknowledge our colleagues Drs. Louise T. Chow, Maria Pellegrini, and Chin Hua Wu for helpful discussions and experimental contributions to the development of these techniques. TRB was supported by a Helen Hay Whitney Fellowship, LMA by a Damon Runyan Fellowship, and NDH by an NSF Fellowship. General research support was received from an NIH grant to ND.

REFERENCES

1. Davis, R.W., Simon, M., and Davidson, N. (1971) *Methods in Enzymology* **21D**, 413-428.
2. Ohtsubo, E., Lee, H-J., Deonier, R.C., and Davidson, N. (1974) *J. Mol. Biol.* **89**, 599-618.
3. Forsheit, A.B., Davidson, N., and Brown, D.D. (1974) *J. Mol. Biol.* **90**, 301-315.
4. Thomas, M., White, R., and Davis, R.W. (1976) *Proc. Nat. Acad. Sci. USA* **73**, 2294-2298.
5. Wu, M. and Davidson, N. (1975) *Proc. Nat. Acad. Sci. USA* **72**, 4506-4510.
6. Reed, S.I. and Alwine, J.C. (1977) *Cell* **11**, 523-531.
7. Wu, M. and Davidson, N. (1973) *J. Mol. Biol.* **78**, 1-21.
8. Angerer, L., Davidson, N. Murphy, W., Lynch, D. and Attardi, G. (1977) *Cell* **9**, 81-90.
9. Sodja, A. and Davidson, N. (1978) *Nuc. Acid. Res.*, following paper.
10. Manning, J.E., Hershey, N.D., Broker, T.R., Pellegrini, M. and Davidson, N. (1975) *Chromosoma (Berl.)* **53**, 107-117.
11. Green, N.M. and Toms, E.J. (1970) *Biochem. J.* **118**, 67-70.
12. Fraenkel-Conrat, H., Snell, N.S., and Ducay, E.D. (1952a) *Arch. Biochem. Biophys.* **80**, 80-96.
13. Green, N.M. (1963a) *Biochem. J.* **89**, 585-591.
14. Heitzmann, H. and Richards, F.M. (1974) *Proc. Nat. Acad. Sci. USA* **71**, 3537-3541.
15. Fischbach, F.A. and Anderegg, R.W. (1965) *J. Mol. Biol.* **14**, 458-473.
16. Becker, J.M., Wilchek, M. and Katchalski, E. (1971) *Proc. Nat. Acad. Sci. USA* **68**, 2604-2607.
17. Jasiewicz, M.L., Schoenberg, D.R., and Mueller, G.C. (1976) *Experimental Cell Research* **100**, 213-217.
18. Pellegrini, M., Oen, H., and Cantor, C.R. (1972) *Proc. Nat. Acad. Sci. USA* **69**, 837-841.
19. Sarin, P.S., and Zamecnik, P.C. (1964) *Biochim. Biophys. Acta* **91**, 653-655.
20. Axen, R., Porath, J., Ernback, S. (1967) *Nature* **214**, 1302-1304.
21. Bodanszky, A. and Bodanszky, M. (1970) *Experientia* **26**, 327.
22. Green, N.M. and Toms, E.J. (1973) *Biochem. J.* **133**, 687-698.
23. Hofmann, K., Finn, F.M., Friesen, H-J., Diaconescu, C., and Zahn, H. (1977) *Proc. Nat. Acad. Sci. USA* **74**, 2697-2700.
24. Penswick, J.R. and Holley, R.W. (1965) *Proc. Nat. Acad. Sci. USA* **53**, 543-546.
25. Granick, S. (1946) *Chem. Revs.* **38**, 379-403.
26. Serwer, P. (1975) *J. Mol. Biol.* **92**, 433-448.
27. Green, N.M. (1963b) *Biochem. J.* **89**, 599-609.
28. Fraenkel-Conrat, H. and Steinschneider, A. (1968) *Methods in Enzymology* **12B**, 243-246.
29. Green, N.M. Konieczny, L., Toms, E.J. and Valentine, R.C. (1971) *Biochem. J.* **125**, 781-794.

Nucleic Acids Research

30. Wintermeyer, W. and Zachan, H.G. (1975) FEBS Letters 58, 306-309.
31. Corutti, P. and Miller, N. (1967) J. Mol. Biol. 26, 55-56.
32. Von der Haar, F., Schlimme, E., and Gauss, D.H. (1971) In Procedures in Nucleic Acid Research, vol. 2, p. 643-664.
33. Gyorgy, P., Rose, C.S. and Tomarelli, R. (1942) J. Biol. Chem. 144, 169-173.
34. Fraenkel-Conrat, H., Snell, N.S., and Ducay, E.D. (1952b) Arch. Biochem. Biophys. 80, 97-107.
35. Green, N.M. (1963c) Biochem. J. 89, 609-620.
36. Cuatrecasas, P., and Wilchek, M. (1968). Biochem. Biophys. Res. Comm. 33, 235-239.
37. Green, N.M. and Ross, M.E. (1968) Biochem. J. 110, 59-66.
38. Manning, J., Pellegrini, M., Davidson, N. (1977) Biochem. 16, 1364-1370.
39. Pellegrini, M., Holmes, D.S. and Manning J. (1977), Nuc. Acids Res. 4, 2961-2974.
40. Yen, P.H., Sodja, A., Cohen, M. Jr., Conrad, S.E., Wu, M., Davidson, N. and Ilgen C. (1977) Cell 11, 763-777.